US20060149224A1 - Surgical instruments and techniques for treating gastro-esophageal reflux disease - Google Patents

Surgical instruments and techniques for treating gastro-esophageal reflux disease Download PDF

Info

Publication number
US20060149224A1
US20060149224A1 US11/365,943 US36594306A US2006149224A1 US 20060149224 A1 US20060149224 A1 US 20060149224A1 US 36594306 A US36594306 A US 36594306A US 2006149224 A1 US2006149224 A1 US 2006149224A1
Authority
US
United States
Prior art keywords
les
tissue
collagen
electrodes
energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/365,943
Inventor
John Shadduck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mederi Therapeutics Inc
Original Assignee
Shadduck John H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shadduck John H filed Critical Shadduck John H
Priority to US11/365,943 priority Critical patent/US20060149224A1/en
Publication of US20060149224A1 publication Critical patent/US20060149224A1/en
Priority to US11/469,816 priority patent/US7507239B2/en
Assigned to RESPIRATORY DIAGNOSTIC, INC. reassignment RESPIRATORY DIAGNOSTIC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CURON MEDICAL, INC.
Assigned to MEDERI THERAPEUTICS, INC. reassignment MEDERI THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RESPIRATORY DIAGNOSTIC, INC.
Priority to US12/368,943 priority patent/US20090187181A1/en
Priority to US12/587,957 priority patent/US20100042091A1/en
Priority to US12/751,803 priority patent/US20100191237A1/en
Priority to US13/325,811 priority patent/US20120083780A1/en
Priority to US13/691,822 priority patent/US8556952B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1485Probes or electrodes therefor having a short rigid shaft for accessing the inner body through natural openings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00005Cooling or heating of the probe or tissue immediately surrounding the probe
    • A61B2018/00047Cooling or heating of the probe or tissue immediately surrounding the probe using Peltier effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00273Anchoring means for temporary attachment of a device to tissue
    • A61B2018/00279Anchoring means for temporary attachment of a device to tissue deployable
    • A61B2018/00285Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00482Digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00482Digestive system
    • A61B2018/00494Stomach, intestines or bowel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00553Sphincter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00666Sensing and controlling the application of energy using a threshold value
    • A61B2018/00678Sensing and controlling the application of energy using a threshold value upper
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00726Duty cycle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00797Temperature measured by multiple temperature sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00815Temperature measured by a thermistor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00821Temperature measured by a thermocouple
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00875Resistance or impedance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • A61B2018/1246Generators therefor characterised by the output polarity
    • A61B2018/1253Generators therefor characterised by the output polarity monopolar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • A61B2018/1246Generators therefor characterised by the output polarity
    • A61B2018/126Generators therefor characterised by the output polarity bipolar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B2018/1467Probes or electrodes therefor using more than two electrodes on a single probe
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/1815Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
    • A61B2018/1861Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves with an instrument inserted into a body lumen or cavity, e.g. a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37Surgical systems with images on a monitor during operation
    • A61B2090/378Surgical systems with images on a monitor during operation using ultrasound
    • A61B2090/3782Surgical systems with images on a monitor during operation using ultrasound transmitter or receiver in catheter or minimal invasive instrument
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/002Irrigation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers

Definitions

  • This invention relates to instruments and techniques for thermally-mediated therapies of targeted tissue volumes in a patient's LES (lower esophageal sphincter) to treat gastro-esophageal reflux disease (GERD) in a minimally invasive manner.
  • the thermally-mediated treatment in a low temperature range, selectively injures cells and proteins within the (LES) to induce a predictable wound healing response to populate the targeted tissue with collagen matrices as a means of altering the bio-mechanical characteristics of the LES.
  • an alternative thermally-mediated treatment is used to shrink native collagen fibers within the LES to “model” the dimensions and laxity of the LES.
  • novel treatment techniques are preferably performed with a trans-esophageally introduced bougie-type instrument and are adapted to take the place of more invasive surgical methods for treating GERD (e.g., Nissen fundoplications) in the treatment of the less severe GERD cases.
  • GERD e.g., Nissen fundoplications
  • Gastro-esophageal reflux disease is a digestive disorder caused by dysfunction in a patient's lower esophageal sphincter (LES). In normal swallowing, the LES progressively opens to allow food to pass into the stomach and thereafter tightens to prevent food and stomach acids from flowing back into the esophagus. Gastro-esophageal reflux occurs when the stomach's contents flow upwardly into the esophagus.
  • such acid reflux results from anatomic abnormalities in the LES and surrounding structures, such as overly relaxed muscle tone within the LES, a shortened esophageal length within the abdominal cavity, insufficient intra-abdominal pressures, and/or from a contributory factor such as a hiatal hernia.
  • Prolonged acid reflux can cause serious complications such as esophagitis, erosions, esophageal bleeding or ulcers.
  • chronic scarring caused by acid reflux can cause narrowing or stricture in the esophagus.
  • Some patients develop Barrett's esophagus which is a form of severe damage to the esophageal lining. It is believed that Barrett's esophagus is a precursor to esophageal cancer.
  • GERD GERD-associated GERD
  • H2-blockers cimetidine, famotidine, nizatidine and ranitidine
  • PPI proton pump inhibitor
  • Another form of drug therapy includes motility drugs for quickening the emptying of stomach contents (cisipride, bethanechol and metclopramide).
  • GERD GERD us caused by an anatomic (mechanical) defect
  • certain surgeries are well suited to correct the defect by effectively lengthening the LES and/or increasing intraluminal pressures within the LES to prevent acid reflux.
  • the leading surgical procedure is an endoscopic Nissen fundoplication, in which the surgeon develops a fold (plication) in the fundus of the stomach and then wraps and sutures the plication generally around the LES to increase intra-esophageal pressures therein.
  • An endoscopic Nissen fundoplication is difficult to perform and typically requires the use of several disposable surgical instruments that are expensive.
  • An open surgery to accomplish a Nissen fundoplication also is possible but undesirable because it requires lengthy postoperative recuperation and results in a long disfiguring upper abdominal incision.
  • the principal objects of this invention are to provide instruments and techniques for least invasive delivery of thermal energy through a tissue surface to a targeted tissue volume to accomplish the controlled remodeling of the treated tissue, and may also be referred to as bulking tissue.
  • the targeted tissues that can be treated in a “least invasive” manner include, but not limited to, soft tissues in the interior of a body (in particular, collagenous tissues such as fascia, ligamentous tissue), collagen-containing walls of vessels and organs, and anatomic structures having, supporting or containing an anatomic lumen (e.g., esophagus, urethra) Such tissues hereafter may be referred to as “targeted” tissue volumes or “target sites”.
  • the invention discloses techniques and instruments that utilize radiofrequency (Rf) energy delivery to selectively injure cells and extracellular compositions (e.g., proteins) in a target site to induce a biological response to the injury—such biological response including cell reproduction to an extent but more importantly the population of the extracellular space with collagen fibers in a repair matrix.
  • Rf radiofrequency
  • the controlled alteration or modeling of the structural and mechanical characteristics of a targeted tissue site is possible by synthesis of new collagen fibers (or “bulking effects”) therein.
  • the above-described objects of the invention are enhanced by controlled manipulation of certain bio-physical characteristics of the target tissue prior to the delivery of Rf energy to induce the injury healing process.
  • another object of the invention is the acute shrinkage of native collagen fibers in the targeted tissue volume. Such acute collagen shrinkage can cause tightening of a targeted tissue volume.
  • the injury healing process in a human body is complex and involves an initial inflammatory response which in collagenous tissues is followed by a subsequent response resulting in the population of new (nascent) collagen in the extracellular space.
  • a mild injury may produce only an inflammatory reaction.
  • More extensive tissue trauma invokes what is herein termed the injury healing response.
  • Any injury to tissue, no matter whether mechanical, chemical or thermal may induce the injury healing response and cause the release of intracellular compounds into the extracellular compartment of the injury site.
  • This disclosure relates principally to induction of the injury healing process by a thermally-mediated therapy.
  • the temperature required to induce the response ranges from about 40° C. to 70° C. depending on the targeted tissue and the duration of exposure.
  • Tncs temperature that causes “new collagen synthesis”.
  • Tsc temperature for acute “shrinkage of collagen”
  • a Rf energy source is provided to selectively induce the injury healing process.
  • a high frequency alternating current e.g., from 100,000 Hz to 500,000 Hz
  • the alternating current causes ionic agitation and friction in the targeted tissue as the ions follow the changes in direction of the alternating current. Such ionic agitation or frictional heating thus does not result from direct tissue contact with a heated electrode.
  • I E/R
  • I the intensity of the current in amperes
  • E the energy potential measured in volts
  • R the tissue resistance measured in ohms.
  • current density or level of current intensity is an important gauge of energy delivery which relates to the impedance of the tissue volume.
  • the temperature level generated in the targeted tissue volume thus is influenced by several factors, such as (i) Rf current intensity (ii) Rf current frequency, (iii) tissue impedance levels within the targeted tissue volume, (v) heat dissipation from the targeted tissue volume, (vi) duration of Rf delivery, and (vii) distance of the targeted tissue volume from the electrodes.
  • a subject of the present invention is the delivery of “controlled” thermal energy to a targeted tissue volume with a computer controlled system to vary the duration of current intensity and frequency together, based on sensor feedback systems.
  • the inflammatory exudate contains fibrinogen which together with enzymes released from blood and tissue cells, cause fibrin to be formed and laid down in the area of the tissue injury.
  • the fibrin serves as a hemostatic barrier and thereafter acts as a scaffold for repair of the injury site.
  • Fibroblasts migrate and either utilize the fibrin as scaffolding or for contact guidance thus further developing a fiber-like scaffold in the injury area.
  • the fibroblasts not only migrate to the injury site but also proliferate During this fibroplastic phase of cellular level repair, a extracellular repair matrix is laid down that is largely comprised of collagen. Depending on the extent of the injury to tissue, it is the fibroblasts that synthesize the collagen within the extracellular compartment as a form of connective tissue (hereafter nascent collagen), typically commencing about 36 to 72 hours after the injury.
  • connective tissue hereafter nascent collagen
  • fibrous connective tissue formation is the single most prevalent tissue in the body and gives structural rigidity or support to tissues masses or layers.
  • the principal components of such connective tissues are three fiber-like proteins-collagen, reticulin and elastin along with a ground substrate.
  • the bio-mechanical properties of fibrous connective tissue and the repair matrix are related primarily to the fibrous proteins of collagen and elastin. As much as 25% of total body protein is native collagen. In repair matrix tissue, it is believed that nascent collagen is in excess of 50%.
  • Collagen is an extracellular protein found in connective tissues throughout the body and thus contributes to the strength of the musculo-skeletal system as well as the structural support of organs. Numerous types of collagen have been identified that seem to be specific to certain tissues, each differing in the sequencing of amino acids in the collagen molecule.
  • Tsc tissue shrink or contract longitudinally when elevated in temperature to the range of 60° C. to 80° C.
  • Portions of this disclosure relate to techniques for controlled shrinkage of collagen fibers in the soft tissue, and more generally to the contraction of a collagen-containing tissue volume, (including both native collagen and nascent collagen) for therapeutic purposes.
  • Collagen consists of a continuous helical molecule made up of three polypeptide coil chains. Each of the three chains is approximate equal length with the molecule being about 1.4 nanometers in diameter and 300 nm. in length along its longitudinal axis in its helical domain domain (medial portion of the molecule). The spatial arrangement of the three peptide chains in unique to collagen with each chain existing as a right-handed helical coil. The superstructure of the molecule is represented by the three chains being twisted into a left-handed superhelix.
  • each collagen molecule is bonded to together by heat labile intermolecular cross-links (or hydrogen cross-links) between the three peptide chains providing the molecule with unique physical properties, including high tensile strength along with moderate elasticity. Additionally, there exist heat stabile or covalent cross-links between the individual coils.
  • the heat labile cross-links may be broken by mild thermal effects thus causing the helical structure of the molecule to be destroyed with the peptide chains separating into individual randomly coiled structures. Such thermal destruction of the cross-links results in the shrinkage of the collagen molecule along its longitudinal axis to up to one-third of its original dimension, in the absence of tension.
  • a plurality of collagen molecules aggregate naturally to form collagen fibers that collectively make up the a fibrous matrix.
  • the collagen fibrils polymerize into chains in a head-to-tail arrangement generally with each adjacent chain overlapping another by about one-forth the length of the helical domain a quarter stagger fashion to form a collagen fiber.
  • Each collagen fiber reaches a natural maximum diameter, it is believed because the entire fiber is twisted resulting in an increased surface are that succeeding layers of fibrils cannot bond with underlying fibril in a quarter-stagger manner.
  • the present invention is directed to techniques and instruments for controlled thermal energy delivery to portions of a patient's LES, in alternative therapies, either:
  • the device of the present invention for “modeling” a collagen matrix in targeted tissue (or “bulking” targeted tissue) in walls of the patient's LES is fabricated as a flexible bougie that carries thermal energy delivery means in its distal working end.
  • an Rf source is connected to at least one electrode carried in the working end.
  • the working end may carry a single electrode that is operated in a mono-polar mode or a plurality of electrodes operated in either a mono-polar or bi-polar manner, with optional multiplexing between various paired electrodes.
  • a sensor array of individual sensors also is carried in the working end, typically including (i) thermocouples and control circuitry, and/or (ii) impedance-measuring circuitry coupled to the electrode array.
  • a computer controller is provided, together with the feedback circuitry from the sensor systems, that is capable of full process monitoring and control of: (i) power delivery; (ii) parameters of a selected therapeutic cycle, (iii) mono-polar or bi-polar energy delivery, and (iv) multiplexing Rf delivery.
  • the controller also can determine when the treatment is completed based on time, temperature, tissue impedance or any combination thereof.
  • the device is introduced through the patient's mouth until the working end and electrode array is positioned within the LES.
  • the therapeutic phase commences and is accomplished under various monitoring mechanisms, including but not limited to (i) direct visualization, (ii) measurement of tissue impedance of the target tissue masses relative to the device, and (iii) utilization of ultrasound imaging before or during treatment.
  • the physician actuates the pre-programmed therapeutic cycle for a period of time necessary to elevate the target tissue mass to Tncs (temperature of new collagen synthesis) which is from 45° to 60° depending on duration of energy delivery.
  • the delivery of thermal energy is conducted under full-process feedback control.
  • the delivery of thermal energy induces the injury healing response which thereafter populates the mass with an extracellular collagen matrix and reduces the flexibility of the LES over the subsequent several days and weeks.
  • the physician thereafter may repeat the treatment.
  • the delivery of Rf energy may be elevated to shrink collagen fibers at a range between 60° to 80° C. to reach Tsc.
  • the effect of such collagen shrinkage is to rigidify or bulk the treated tissue volumes in the wall of the LES.
  • the treatment can be repeated until the desired increase in intra-esophageal pressures is achieved. It is believed that such periodic treatments (e.g., from 2 to 6 treatments over a period of several weeks) may be best suited to treat the LES.
  • the present invention advantageously provides least invasive thermally-mediated techniques for increasing intraluminal pressures in a patient's LES to prevent gastro-esophageal reflux.
  • the present invention provides novel devices and techniques for thermally inducing an injury healing response to alter cellular/extracellular architecture in the LES.
  • the present invention provides techniques for thermal induction of bulking of tissue volumes around a sphincter in an anatomic lumen.
  • the present invention advantageously provides an electrode array fur delivering a controlled amount of Rf energy to a specific targeted tissue volume in the LES having a particular shape or pattern.
  • the present invention provides an electrode array for delivering a controlled amount of Rf energy to a specific target collagen-containing tissue volume to achieve a controlled contraction of the collagen fibers therein.
  • the present invention provides a novel device and technique for contraction of collagen fibers around the lumen of an anatomic structure to reduce the dimension of the lumen.
  • the present invention also provides an instrument and method in which a bougie-type member has a working channel to accommodate an endoscope, an accessory instrument or for therapeutic agent delivery or suction.
  • the present invention advantageously provides a device that is inexpensive and disposable. Additional advantages and features of the invention appear in the following description in which several embodiments are set forth.
  • FIG. 1 is a perspective view of a Type “A” device and Rf energy source of the present invention.
  • FIG. 2 is transverse sectional view of the device of FIG. 1 taken along line 2 - 2 of FIG. 1 .
  • FIG. 3A is an enlarged perspective view of the working end of the device of FIG. 1 .
  • FIG. 3B is transverse sectional view of the working end of FIG. 3A taken along line 3 B- 3 B of FIG. 3A .
  • FIG. 4 is a perspective view of an alternative embodiment of working end similar to FIG. 3A .
  • FIGS. 5A-5F are views of a portion of the wall of a lower esophageal sphincter (LES) showing various patterns of thermally-mediated treatments developed by various electrode arrays.
  • LES lower esophageal sphincter
  • FIG. 6A is a view of an alternative embodiment of working end similar to that of FIG. 3A .
  • FIG. 6B is an alternative embodiment of working end showing a working channel.
  • FIG. 6C is a block diagram of the Rf source of the invention including a computer controller.
  • FIGS. 7A-7D are schematic views of a method of thermally-mediated treatment of the LES utilizing the device of FIG. 1 ;
  • FIG. 7A being a view of positioning the working end in the region of the LES;
  • FIG. 7B being a view of expansion of an optional balloon carried at the working end;
  • FIG. 7C being a view of sectional view of the working end taken along line 7 C- 7 C of FIG. 7B showing the targeted tissue region; and, FIG. 7D showing the tissue dimensions following a thermally mediated therapy.
  • FIGS. 8A-8B are views of the working end of a Type “B” of device for thermally-mediated therapies of the LES and its means of capturing the wall of the LES for treatment.
  • FIG. 9 is a view of the working end of an alternative Type “B” devices similar to the device FIGS. 8A-8B .
  • FIG. 10 is a view of a portion of the wall of the LES showing a method of treatment with a Type “B” device.
  • FIG. 11A is a view of the working end of another alternative Type “B” with rolling components.
  • FIG. 11B is a view of a portion of the wall of the LES showing a method of treatment with the working end of FIG. 11A .
  • FIG. 12A is a view of the working end of yet another Type “B” device.
  • FIG. 12B is a view of a portion of the wall of the LES showing a method of treatment with the working end of FIG. 12A .
  • FIG. 13A is a view of a Type “C” device system for thermally-mediated treatments of the LES.
  • FIG. 13B is a view of the working end of a component of the Type “C” system of FIG. 13A .
  • FIG. 13C is a views of an alternative working end similar to that of FIG. 13B .
  • FIG. 14 is a view of the wall of the LES showing a method of treatment with the Type “C” system of FIG. 13A .
  • FIG. 15 is a view of the working end of another Type “C” device
  • Type “A” Device for Thermally-Mediated LES Therapy 1.
  • FIG. 1 depicts LES treatment device 5 that is to be utilized for a thermally-mediated alteration of the cellular/extracellular architecture of a lower esophageal sphincter (LES) while at the same time sizing or gauging the lumen of the esophagus.
  • device 5 comprises elongate extension member 10 with proximal end 11 and working end 15 with distalmost tip 16 .
  • extension member 10 has a generally cylindrical shape along longitudinal axis 17 with an overall length of approximately 60 to 90 centimeters.
  • the cross-sectional dimension of extension member 10 would typically range in diameters from #40 to #60 French for various patients having varied esophageal anatomies (but may be much smaller as described below for introduction through a working channel of a flexible gastroscope).
  • the extension member 10 preferably is capable of bending in an approximately 1.0 cm. radius (or less) and may comprise a flexible plastic casing 18 with a high-density liquid, gel or other suitable flexible core 19 inside the casing and the tapered tip.
  • the device may compare in size and flexibility to a commercially available bougie that is adapted to push through an esophagus to enlarge the lumen, such as a bougie manufactured by Pilling Weck, 420 Delaware Drive, Fort Washington, Pa.
  • an Rf energy source 40 is provided for delivering thermal energy to portions of the LES.
  • the Rf energy source 40 may alternatively be replaced with a microwave source, or another known source of thermal energy such as a laser. It further should be appreciated that other sources of energy such as ultrasound or high-energy focused ultrasound (HIFU) that are known in the art may be utilized to cause thermally-mediated treatments of target sites in the LES.
  • the Rf energy source 40 is detachably connected to extension member 10 by power cable 42 .
  • the working end 15 carries at least one electrode in an electrode array 44 , and preferably carries a plurality of Rf electrodes 45 a - 45 n that are positioned in the surface 46 of working end 15 .
  • FIGS. 1 and 3 A show two exemplary electrodes 45 a - 45 b arranged longitudinally in extension member 10 in a spaced relationship in surface 46 .
  • the electrodes 45 a - 45 b shown in FIG. 3 may be operated in a mono-polar mode (with groundplate) but preferably are operated in a bi-polar mode to provide controlled energy delivery to achieve a particular temperatures between the adjacent paired electrodes 45 a - 45 b in the wall W of the LES proximate to the electrodes.
  • the electrodes are of any suitable biocompatible conductive material which conduct current to and from tissue around the LES in direct contact with electrodes 45 a - 45 b.
  • Expansion means are preferably (but optionally) carried in working end 15 for increasing the transverse dimension of the working portion and for pressing any electrodes 45 a - 45 n securely against a wall of the lumen of the LES.
  • Inflatable balloon 50 is capable of collapsed and inflated conditions and is depicted in FIG. 1 (phantom view of inflated condition) and FIGS. 3A and 3B in an inflated condition. Balloon 50 is incorporated into the wall of extension member 10 in this embodiment generally on the opposite side from electrodes 45 a - 45 b .
  • Balloon 50 preferably is made of an elastomeric material, for example silicone or latex and has chamber 52 that is inflatable to a maximum transverse dimension of approximately 10 to 30 millimeters at low pressures (e.g., from 0.5 to 5 psi).
  • a Luer-type fitting 53 is coupled to tube 54 that is provided in core 19 of extension member and communicates with an inflation source to inflate balloon 50 , for example a syringe with saline solution or air ( FIG. 1 ).
  • expansion means of the invention is shown as balloon 50 but such expansion means also may comprise any type of suitable mechanical expansion structure disposed within the core of working end 15 that is adapted to expand the cross-section of the working portion that is known in the art (e.g., flexible ribs that are actuated with a pull cable).
  • Visible and/or radiopaque and markings 57 are shown in FIG. 1 and are used to both angularly and axially position the working end 15 of the device within the patient's LES.
  • the markings 57 in the proximal portion of extension member 10 are useful to the anesthesiologist or physician's assistant to gauge the depth of insertion of the device as well as its rotational angle.
  • this particular embodiment of device 5 has electrodes 45 a - 45 b each with an elongate shape with the electrodes being longitudinally oriented in relation to axis 17 of extension member 10 .
  • the electrodes 45 a and 45 b have a length ranging from about 5.0 mm. to 15.0 mm. and a width ranging from 0.25 mm. to 2.5 mm.
  • the spacing dimension d between the electrodes may range from about 0.5 mm. to 10.0 mm.
  • FIGS. 3A-3B show a variant of device 5 with two electrodes 45 a and 45 b , it should be appreciated that a plurality of greater than two electrodes may be carried in particular spaced relationships along working end 15 , as shown in FIG. 4 .
  • the alternative embodiment is shown with six longitudinal electrodes 45 a - 45 f .
  • the embodiment of FIG. 4 thus may be operated in a mono-polar mode or in a bi-polar mode with a computer controller 60 (see FIG. 1 ) operatively connected to the Rf source 40 and electrodes and temperature sensors to multiplex (of vector) the current flow between and among various paired electrodes.
  • working end 15 may carry only a single electrode operated in a mono-polar mode and fall within the scope of the invention).
  • the elongate configuration of the electrodes and their longitudinal orientation was selected because it is believed that Rf energy delivery to elongate regions of the LES will prove optimal to accomplish the objectives of methods of the invention.
  • functional portions of the lower esophageal sphincter extend as much as several cm. from the gastro-esophageal junction and it is believed that the disclosed thermally-mediated treatments of collagen synthesis should extend over a substantial axial dimension of the LES.
  • another the objective may be collagen shrinkage based on anatomic dimensions and motility studies of a particular patient. Further, the diagnosis may indicate that such collagen shrinkage is desired in a localized annular or part annular region.
  • FIG. 5A shows a singular annular (circumferential) pattern of treated tissue indicated at T in the wall W of a lower esophageal sphincter to shrink collagen and slightly reduce the dimension of the lumen by creating bulk in region T.
  • treated tissue patterns are shown in portions of wall W (member 10 in phantom view) and it can be understood that electrodes may be of particular configuration to deliver such treatment locations and patterns.
  • a single electrode operated in a mono-polar mode can develop the targeted treatment band T of FIG.
  • FIG. 5A shows two parallel electrodes operated in a bi-polar mode may cause the targeted treatment band T of FIG. 5A by energy flow therebetween).
  • FIG. 5B shows multiple annular regions or bands of treated tissue T.
  • FIG. 5C illustrates a multiplicity of treatment regions T as when the objective is the delivery of Rf energy in a diffuse manner over a substantial portion of wall W.
  • FIG. 5D illustrates a plurality of helical treatment regions T which would result in diffuse effects if the regions were close together.
  • FIG. 5E illustrates a v-shaped or chevron-shaped treatment regions T.
  • FIG. 5F is a more greatly enlarged view of wall W with treated regions T multiple electrodes 45 a - 45 n in phantom view.
  • any of the elongate electrodes of FIG. 5A-5E may be configured as multiple intermittently-spaced electrodes and optionally may operate in a bi-polar and multiplexed mode with varied possible vectors between various paired electrodes. Only certain electrodes may delivery current, all for a controlled periods of time.
  • the multiplexer also may cause the Rf energy delivery to switch between mono-polar and bi-polar during a treatment.
  • the electrodes are of any suitable conductive material which is adapted to deliver Rf energy to soft tissue in the walls W of the LES around the esophageal lumen without ablating (and necrosing) any surface tissue to significant degree.
  • the electrode material may include gold, nickel titanium, platinum, stainless steel, aluminum and copper.
  • Each individual electrode of the array is connected to Rf source 40 and controller 60 by a suitable current-carrying wires 61 a - 61 n within introducer member 10 . The proximal portions of such current-carrying wires are carried in power cable 42 that connects with Rf source 40 .
  • a sensor array of individual sensors 65 a - 65 b (an number of sensors are possible) also is provided in a spaced relationship around working end 15 .
  • the sensor array will typically include thermocouples or thermisters to measure temperature levels of an electrode or of a portion of the wall W in contact with the sensor.
  • the sensor array includes impedance sensing capabilities (not shown) that measures tissue impedance in a conventional manner between particular electrode elements at the controller 60 as described below.
  • Current-carrying wires 66 a - 66 b are shown in FIGS. 2-3A are connected to sensors 65 a - 65 b .
  • Other wires may be provided in the device that could be dedicated specifically to measuring tissue impedance.
  • One or more such impedance monitoring systems may be used to confirm prior to the therapeutic cycle that a satisfactory coupling of energy will be accomplished. Impedance is monitored between each electrode and a groundpad when operated in a mono-polar mode, or between various electrodes when operated in a bi-polar mode.
  • FIG. 6A Another embodiment of a Type “A” device 5 is shown in FIG. 6A wherein an ultrasound source 70 may be coupled to one or more ultrasound transducers 72 (collectively) in a spaced relationship in working end 15 of extension member 10 .
  • An output of ultrasound source 70 optionally in combination with Rf source 40 , any be adapted to deliver thermal energy to the LES.
  • Each ultrasound transducer 72 may be a piezoelectric crystal mounted on a suitable substrate.
  • a conventional ultrasound lens of electrically insulated material is fitted between the exterior of surface 18 of working end 15 and the piezoelectric crystal which is connected by electrical leads in extension member to ultrasound source 70 .
  • Each ultrasound transducer thus is capable of transmitting ultrasound energy into the target tissue of the LES for imaging purposes or high-energy ultrasound (HIFU) to deliver thermal energy.
  • Thermocouples can provide accurate temperature measurements of surface temperatures at various points along the esophageal lumen. Such thermal sensors are preferably adjacent to piezoelectric crystals.
  • FIG. 6B shows another embodiment of device 5 with a working channel 76 , with an open proximal end in the proximal end 11 of the device with a distal termination (not shown) at the distal end of the device.
  • the working channel 76 may be any suitable dimension, for example from about 0.5 mm. to 5.0 mm. or more, to accommodate a flexible shaft accessory instrument (e.g., an endoscope or forceps).
  • Working channel 76 also may be utilized to deliver therapeutic agents to the patient's stomach or to suction air or liquid secretions from the stomach.
  • the controller 60 includes a CPU coupled to the Rf source and multiplexer 80 through a bus. Associated with the controller system may be a keyboard, disk drive or other non-volatile memory system, along with displays that are known in the art for operating such a system.
  • the operator interface may include various types of imaging systems for observing the treatment such as thermal or infrared sensed displays, ultrasonic imaging displays or impedance monitoring displays.
  • the multiplexer 80 is driven by controller 60 (digital computer) which includes appropriate software 82 .
  • Thermocouples 65 carried in a position proximate to the electrodes together with additional thermal sensors positioned within the Rf source or generator are adapted to measure energy delivery (current and voltage) to each electrode at the site of targeted tissue during a therapeutic cycle.
  • the output measured by thermal sensors is fed to controller 60 in order to control the delivery of power to each electrode location.
  • the controller 60 thus can be programmed to control temperature and Rf power such that a certain particular temperature is never exceeded at a targeted treatment site.
  • the operator further can set the desired temperature which can be maintained.
  • the controller 60 has a timing feature further providing the operator with the capability of maintaining a particular temperature at an electrode site for a particular length of time.
  • a power delivery profile may be incorporated into controller 60 as well as a pre-set for delivering a particular amount of energy.
  • a feedback system or feedback circuitry can be operatively connected to the impedance measuring system, and/or the temperature sensing system or other indicators and to the controller 60 to modulate energy delivery at Rf source 40 .
  • controller 60 can determine when the treatment is completed based on time, temperature or impedance or any combination thereof.
  • process variables can be controlled and varied as tissue temperature is measured at multiple sites in contact with the sensor array, as well as by monitoring impedance to current flow at each electrode which indicates the current carrying capability of the tissue during the treatment process.
  • Controller 60 can provide multiplexing along various vectors as previously described, can monitor circuit continuity for each electrode and can determine which electrode is delivering energy.
  • the amplifier 85 is a conventional analog differential amplifier for use with thermisters and transducers.
  • the output of amplifier 85 is sequentially connected by analog multiplexer 80 to the input of analog digital converter 86 .
  • the output of amplifier 85 is a particular voltage that represents the respective sensed temperatures.
  • the digitized amplifier output voltages are supplied to microprocessor 88 .
  • Microprocessor 88 thereafter calculates the temperature and/or impedance of the tissue site in question.
  • Microprocessor 88 sequentially receives and stores digital data representing impedance and temperature values. Each digital value received by microprocessor corresponds to a different temperature or impedance at a particular site.
  • the temperature and impedance values may be displayed on operator interface as numerical values.
  • the temperature and impedance values also are compared by microprocessor with programmed temperature and impedance limits. When the measured temperature value or impedance value at a particular site exceeds a pre-determined limit, a warning or other indication is given on operator interface and delivery of Rf energy to a particular electrode site can be decreased or multiplexed to other electrodes.
  • a control signal from the microprocessor may reduce the power level at the generator or power'source, or de-energize the power delivery to any particular electrode site.
  • Controller 60 receives and stored digital values which represent temperatures and impedance sent from the electrode and sensor sites. Calculated skin surface temperatures may be forwarded by controller 60 to display and compared to a predetermined limit to activate a warning indicator on the display.
  • FIGS. 7A-7D Operation and use of the instrument shown in FIG. 1 (with two electrode 45 a - 45 b embodiment) in performing the method of the present invention can be described briefly as follows ( FIGS. 7A-7D ).
  • the physician or an assistant introduces working end 15 of device 5 through the patient's mouth into lumen 100 of esophagus 102 .
  • the physician advances extension member 10 distally and rotationally until working end 15 and electrodes 45 a and 45 b are in a suitable position within the LES (see FIG. 7A ).
  • the physician also may advance and turn the instrument to a correct angle by reference to markings 57 on the proximal portion of the device (see FIG. 1 ).
  • the targeted tissue is in a quadrant at the patient's left side or at the anterior of the LES (see FIGS. 7A-7B ). It is believed the area of treatment will vary from patient to patient as determined by motility studies and anatomic characteristics, and probably most cases will involve treatments in several angular positions within the LES.
  • extension member 10 may fit somewhat loosely or snugly in esophageal lumen 100 depending on the diameter of device selected.
  • the physician preferably (but optionally) inflates balloon 50 with an inflation medium, for example air or saline solution from a syringe (not shown).
  • Balloon 50 is inflated to a sufficient dimension to press the surface of working end 15 , and more particularly electrodes 45 a and 45 b , into firm contact with surface 104 of targeted tissue in wall W of the LES.
  • a flexible fiberscope 105 (phantom view) may introduced through a optional working channel 76 to view the gastro-esophageal junction 108 from inside the patient's stomach 110 which may be useful in positioning the device (see FIG. 7B )).
  • the physician selects the treatment site based on anatomical knowledge of the LES and is thus capable of avoiding thermal energy delivery to certain areas or sides of the LES if so desired.
  • the physician commences the therapeutic phase of Rf delivery under various monitoring mechanisms, including but not limited to, (i) measurement of tissue impedance of the target tissue to determine electrical conductivity between the targeted tissue and the electrode arrangement of device 5 , (ii) utilization of ultrasound imaging before and/or during treatment to establish a baseline and duty-cycle tissue characteristics for comparative measurements; and optionally (iii) direct visualization via a fiberscope introduced through a working channel into the stomach and articulated ( FIG. 7B ).
  • a small diameter flexible scope could be positioned within lumen 100 to view the location of working end 15 .
  • the physician may actuate the controller to perform a first modality of treatment described above as a collagen synthesis modality.
  • the controller actuates a pre-programmed therapeutic cycle for a period of time necessary to elevate the targeted tissue T to a particular time/temperature range based on feedback from the sensor system.
  • the cycle can elevate temperatures in the tissue to a range between 40° C. to 70° C. for a period of time ranging from 60 seconds to 10 minutes. More preferably, the therapeutic cycle would elevate temperatures in wall W of the LES to a range between 45° C. and 65° C. for a period of time ranging from 60 seconds to 5 minutes. Still more preferably, the therapeutic cycle would include temperatures in a range between 50° C. and 60° C.
  • the thermal effects will selectively injures cells in and below the surface 104 of wall W at target sites T thus inducing the desired injury healing response.
  • the depth of thermal penetration into the target tissue sites T is determined by the current intensity and duration, and most importantly the thermal relaxation time of the tissue, to preferably effect selective heating of tissue at a depth of about 0.5 mm. to 2.5 mm. from the surface 104 of the wall W of the lumen 100 .
  • electrodes 45 a and 45 b are in direct contact with tissue surface 104 of wall W along the tissue-electrode interface.
  • the controller 60 will sense temperatures along the tissue-electrode interface by means of the sensor array and/or impedance monitoring system and maintain temperature at the tissue surface 104 at a level below that which ablate the surface, generally by lowering the current intensity or making the energy delivery intermittent.
  • the effect of elevating the temperature of the interior of wall W of the LES without surface ablation can be accomplished because of surface cooling caused by conduction of heat into lumen 100 and the heat-absorbing (heat-sink) characteristics of the working end 15 and extension member 10 .
  • the delivery of energy is preferably conducted under full-process feedback control, and in fact the treatment phase may require little attention by the physician ft should be appreciated that the target tissue can be treated uniformly, or various discrete portions of the target tissue can be treated selectively.
  • different levels of current can be delivered to different electrode elements, or current can be multiplexed through various electrodes along different vectors as described previously).
  • a follow-on portion of the therapeutic cycle may comprise a diagnostic phase to gauge the success of the treatment.
  • diagnosis may be accomplished through (i) direct visualization, (ii) ultrasound imaging, (iv) infrared imaging, or (v) temperature measurements.
  • the patient can return to normal activities with periodic monitoring of the intra-esophageal pressure of the LES as well as muscle response of the LES in conventional motility studies. Thereafter, the same treatment may be repeated until alterations in cellular/extracellular architecture increases intraluminal pressures within the LES to the desired level. It is believed that periodic treatments (e.g., 1 week to 2 weeks between treatments) is best suited to alter the mechanical characteristics of the LES.
  • the thermally-mediated treatment induces a bodily response which includes populating the targeted tissue sites T with nascent collagen in the extracellular spaces, which after periodic treatments will make walls W of the LES to be bulked up or thicker and which will cause a reduced cross-section of lumen 100 within the LES.
  • the physician elects to tighten the LES to a greater extent, he may in an initial treatment or in subsequent treatment, perform a different modality of thermally-mediated treatment described above as the collagen shrinkage modality.
  • the physician elects to deliver elevated levels of Rf energy to contract or shrink collagen fibers to further tighten or reduce the flexibility of target tissue T within wall portions of the LES.
  • the delivery of Rf energy will shrink collagen fibers as described above in the LES without significant modification of adjacent tissue volumes.
  • the temperature gradients described above can be accomplished to achieve the temperature to contract collagen fibers in the targeted tissue without increasing the temperature of the surface 104 so that the surface tissue will not be ablated, blistered or necrosed.
  • the energy level is monitored and controlled as to each individual electrode as detailed above by controller 60 .
  • the energy delivery is continuously changed based on sensor inputs which includes temperature data and impedance data from the sensors provided in the device.
  • a pre-programmed therapeutic cycle is selected to achieve shrinkage of native collagen.
  • the delivery of energy is controlled to elevate temperatures in target tissue T to a range generally between 60° C. to 80° C.
  • the therapeutic cycle can be controlled to attain temperatures in the targeted tissue in a range from 60° C. and 70° C. for a period of time ranging from 60 seconds to 5 minutes. Immediate acute longitudinal shrinkage of collagen fibers and molecules will occur in such a temperature range.
  • the targeted tissue T shrink generally in the direction of collagen fibers therein and will make the walls around the lumen of the esophagus somewhat tighter and resistant to radial extension (opening).
  • the collagen fibers and molecules are increased greatly in caliber, as described above, thus causing a bulking up of the targeted tissue in the LES (see FIG. 7D ).
  • the native collagen (and collagen matrices) will bulk up and tighten the targeted tissue sites T as shown in FIG. 7D .
  • the follow collagen shrinkage therapy can be enhanced since both the nascent and native collagenous tissue will shrink within the target tissue sites T. Each subsequent treatment not only will populate the tissue sites T with additional nascent collagen fibers, but also shrinks the nascent collagen fibers from the prior treatment or treatments.
  • Type “B” Device for Thermally-Mediated LES Therapy 1.
  • FIGS. 8A-8B and 9 depict an alternative type of LES treatment device that may be utilized for Rf energy delivery to wall portions W of the LES to alter its cellular/extracellular architecture.
  • the system includes an embodiment of elongate device or member 205 with a medial extending portion 206 that is substantially similar to the Type “A” device described above, and elements common to both the Type “A” and Type “B” embodiment will be described with the same reference numerals.
  • the working end 215 of this embodiment carries a tissue-engaging means known in the art comprising an openable/closeable arm structure for engaging target tissue in the wall of the LES (Cf. the openable/closeable arm structure of related Provisional Application Ser.
  • FIG. 8A shows a longitudinally-oriented arm structure with arm elements 216 a and 216 b that are rotatable around pivots 217 a and 217 b and are optionally covered within a thin flexible sheath 218 that carries longitudinal electrodes 245 a and 245 b .
  • FIG. 8B shows that arm elements 216 a and 216 b are articulatable from a proximal handle of the device by cables and articulating means known in the art thereby to capture tissue of wall W therebetween.
  • the electrodes may be carried directly on the arm elements without a covering sheath. The sheath, however, is preferred to make the instrument perform similar to a bougie for ease of introduction into a patient's esophagus.
  • the elongate device 205 further may include an inflatable collar 220 that can be inflated with any suitable medium, for example air or saline solution from a syringe (not shown).
  • Collar 220 is shown in phantom view in an inflated condition and is position around a distal portion of the device. Collar 220 is sufficiently large to prevent it from passing through GE-junction as the device is lifted proximally and thus may serve as a means of positioning electrodes 245 a and 245 b and the articulating arm elements in the LES.
  • FIG. 10 a portion of the wall of the LES is shown in sectional view in FIG. 10 being captured and engaged by arm elements 216 a and 216 b (phantom view) of working end 215 .
  • the sectional view depicts the targeted tissue T as a hatched regions in interiors of the wall W of the LES as when Rf energy is delivered in a bi-polar manner between the paired electrodes (mono-polar flow also is possible).
  • the treatment may be in a single location or repeated in a plurality of locations.
  • gripping elements known in the art may be configured in the sheath or arm elements to grip tissue (e.g., penetrating elements; tissue gripping studs, or suction apertures communicating with remote suction source) and are intended be encompassed by the scope of the invention.
  • tissue e.g., penetrating elements; tissue gripping studs, or suction apertures communicating with remote suction source
  • FIG. 11A illustrates another embodiment of Type “B” device in which roller elements 250 a and 250 b are carried in arm elements 216 a and 216 b to progressively the engage the wall W of the LES and delivery Rf energy between various paired electrodes 245 a - 245 n in the roller elements 250 a and 250 b .
  • This manner of Rf energy delivery was disclosed in Provisional Application Ser. No. 60/024,974 filed on Aug. 30, 1996 and follow-on patent application Ser. No. 09/920,291 filed on Aug. 28, 1997, and incorporated therein Provisional Application Ser. No. 60/022,790 filed on Jul.
  • FIG. 11B is a sectional view of a small portion of the LES with a wall W engaged between rollers 250 a and 250 b and targeted tissue T receiving Rf energy as described above.
  • FIG. 12A Another variant of Type “B” device is shown in FIG. 12A in which articulating arm elements 252 a and 252 b are carried in a manner to engage the wall W of the LES at 90° to the previously described embodiment.
  • the articulating elements 252 a and 252 b are adapted to capture a portion of wall W treat tissue in a fold around a part of a circumference of the LES rather than in a longitudinal fold described previously.
  • FIG. 12B is a view of a small portion of the LES with a wall W engaged by articulating elements 252 a and 252 b and further indicating targeted tissue T receiving Rf energy in any of the manners described previously.
  • Type “C” System for Thermally-Mediated LES Therapy 4.
  • FIGS. 13A-13C depict an alternative of LES treatment system that may be utilized for performing the above-described methods of treating a lower esophageal sphincter, but this time with the assistance of a separate device from the exterior of the LES in an endoscopic procedure.
  • an intraluminal device is used to size or gauge lumen 100 of the esophagus 102 .
  • the system includes intraluminal esophageal device 305 which is substantially similar to the Type “A” device described above, and hereafter will have similar elements described with the same reference numerals as used above in the Type “A” device.
  • the intraluminal device 305 further includes an inflatable collar 307 that can be inflated with any suitable medium, for example air or saline solution from a syringe (not shown). Collar 307 is shown in phantom view in an inflated condition and is position around a distal portion of the device. Collar 307 is sufficiently large to prevent it from passing through the GE-junction as the device is lifted proximally as a means of positioning electrodes 45 a - 45 n in the LES.
  • any suitable medium for example air or saline solution from a syringe (not shown).
  • Collar 307 is shown in phantom view in an inflated condition and is position around a distal portion of the device. Collar 307 is sufficiently large to prevent it from passing through the GE-junction as the device is lifted proximally as a means of positioning electrodes 45 a - 45 n in the LES.
  • Intraluminal device 305 cooperates with extraluminal device 310 also shown in FIG. 13A-13C .
  • the extraluminal device 310 has elongate introducer member with proximal end 310 a and is adapted for introduction in the interior of the body through a cannula (e.g., a 5-20 mm. trocar sleeve) working end 315 is carried in the distal portion of introducer member 310 a and comprises an articulatable of flexible section 320 section that has a esophagus-contacting surface portion 322 .
  • the esophagus-contacting portion 322 may be substantially planar (see FIG. 13B ) but preferably has an at least partial circumferential receiving surface 323 for fitting closely around the esophagus 102 when intraluminal device 305 is positioned within lumen 100 of the esophagus (see FIG. 13C ).
  • the extraluminal device 310 has at least one and preferable a plurality of electrodes 345 a - 345 n within working end 315 .
  • FIG. 14 shows in a (sectional) perspective view that the electrodes 345 a - 345 n of extraluminal device 310 are adapted to cooperate with electrodes 45 a - 45 b of intraluminal device 305 .
  • the electrodes of the two devices, 305 and 310 preferably are adapted to operate in a bi-polar manner with current passing from the extraluminal device to the intraluminal device or vice versa, or in a bi-polar manner between paired electrodes in the extraluminal member with the intraluminal electrodes not activated but facilitating current flow through wall W (or vice versa).
  • the bi-polar operation of the device may be along a various multiplexed vectors as described previously.
  • the extraluminal device may have all the temperature sensing capabilities, impedance monitoring capabilities, and other feedback capabilities of the Type “A” device described above.
  • extraluminal device may be used to deliver a thermally-mediated treatment as described above, but only from the exterior of the esophagus to targeted tissue in the LES.
  • Rf energy delivery only from the exterior of the LES may be preferred because it would then be unnecessary to elevate the temperature of surface 104 or mucous membrane of the esophageal lumen 100 .
  • the exterior approach logically would be performed only when the surgeon needed to endoscopically access the patient's abdominal cavity for other reasons, e.g., to treat a hiatal hernia that sometimes contributes to GERD.
  • the intraluminal device may simply be a conventional bougie to “stent” the esophagus while performing the thermally-mediated Rf treatment of the LES from its exterior with device 310 .
  • FIG. 14 shows the positioning of the devices 305 and 310 in a manner of practicing a method of the invention
  • the extraluminal device may have an articulatable working end so that the esophagus-contacting portion may be easily oriented to lay against the LES.
  • Such a working end may be hinged or flexible by any suitable means (e.g., a pull wire or reciprocating rod mechanism), with the specific articulation characteristics partly dependent on the location of the port which is used to introduce the device into the patient's body.
  • FIG. 15 depicts another embodiment of LES treatment device 335 that may be utilized for thermally-mediated treatment of the LES from its exterior in an endoscopic procedure.
  • This embodiment of extraluminal device has any suitable closing mechanism for closing the at least two esophagus-contacting portions 336 a and 336 b around the LES and esophagus.
  • Such an embodiment would allow the delivery of thermal energy at least partly around the circumference of the LES, and even entirely around the circumference of the LES if so desired.
  • This embodiment would require that the distal esophagus and LES be mobilized before utilizing the device.
  • this device would find use in cases that require repair of a hiatal hernia wherein mobilization of the distal esophagus is required.
  • the two esophagus-contacting portions 336 a and 336 b are actuated by reciprocation of sleeve 340 over cam-type elements 342 a and 342 b.
  • intraluminal and extraluminal devices are preferably indexable by any suitable means, by which is meant that it would be desirable to have electrodes of the intraluminal device and the electrodes of the cooperating extraluminal device maintainable in a particular alignment or registration, both axially and angularly.
  • a preferable means is to provide a fiber optic light source in the intraluminal component of the system that will transilluminate the wall W of the LES, thereby allowing the physician to position markings (or apertures) on the extraluminal device relative to the points of transillumination.
  • the two esophagus-contacting portions of the extraluminal instrument are preferably made of a transparent plastic material.
  • the surface 18 of working end 15 may carry cooling means as known in the art, wherein cooling lumens may circulate a coolant fluid within the extension member to maintain the surface 104 of the esophageal lumen 100 at a cooled temperature.
  • the extension member may carry the semiconductor Peltier cooling means disclosed in co-pending U.S. patent application Ser. No. 09/110,065 filed Jul. 3, 1998 titled Semiconductor Contact Lens Cooling System and Technique for Light-Mediated Eye Therapies.
  • thermally-mediated treatments disclosed herein may be accomplished with penetrating needle-type electrodes in a working end 15 as known in the art that can be actuated from a handle portion of an elongate member although this is not a preferred approach.
  • the device can be utilized to selectively injure cells to induce a biological response to populate target tissue site T with a collagen fiber matrix.
  • the device further can be utilized to contract collagen-containing tissue volumes to reduce the diameter of the lumen of LES. It can be readily understood that such techniques of tissue modeling may be applied to other lumens of other anatomic structures in the body.
  • a treatment for urinary incontinence can be effected to shrink tissue, tighten tissue or rigidify tissue with a collagen matrix around the urethra with a trans-urethral Rf instrument.
  • tissues around a patient's soft palates can be treated.

Abstract

Instruments for thermally-mediated treatment of a patient's lower esophageal sphincter (LES) to induce an injury healing response to thereby populate the extracellular compartment of walls of the LES with collagen matrices to altere the biomechanics of the LES to provide an increased intra-esophageal pressure for preventing acid reflux. A preferred embodiment is a bougie-type device for trans-esophageal introduction that carries conductive electrodes for delivering Rf energy to walls of the LES (i) to induce the injury healing response or (ii) to “model” collagenous tissues of the LES by shrinking collagen fibers therein.

Description

    RELATED APPLICATIONS
  • This application is a divisional of co-pending U.S. application Ser. No. 10/780,027, filed Feb. 17, 2004, which is a divisional of co-pending U.S. application Ser. No. 09/222,501, filed Dec. 29, 1998 (now U.S. Pat. No. 6,740,082), which claims the benefit of provisional U.S. Application Ser. No. 60/086,068, filed May 20, 1998, and entitled “Surgical Instruments and Techniques for Treating Gastro-Esophageal Reflux Disease.”
  • FIELD OF THE INVENTION
  • This invention relates to instruments and techniques for thermally-mediated therapies of targeted tissue volumes in a patient's LES (lower esophageal sphincter) to treat gastro-esophageal reflux disease (GERD) in a minimally invasive manner. The thermally-mediated treatment, in a low temperature range, selectively injures cells and proteins within the (LES) to induce a predictable wound healing response to populate the targeted tissue with collagen matrices as a means of altering the bio-mechanical characteristics of the LES. In a slightly higher temperature range, an alternative thermally-mediated treatment is used to shrink native collagen fibers within the LES to “model” the dimensions and laxity of the LES. The novel treatment techniques are preferably performed with a trans-esophageally introduced bougie-type instrument and are adapted to take the place of more invasive surgical methods for treating GERD (e.g., Nissen fundoplications) in the treatment of the less severe GERD cases.
  • BACKGROUND OF THE INVENTION
  • Gastro-esophageal reflux disease (GERD) is a digestive disorder caused by dysfunction in a patient's lower esophageal sphincter (LES). In normal swallowing, the LES progressively opens to allow food to pass into the stomach and thereafter tightens to prevent food and stomach acids from flowing back into the esophagus. Gastro-esophageal reflux occurs when the stomach's contents flow upwardly into the esophagus. Typically, such acid reflux results from anatomic abnormalities in the LES and surrounding structures, such as overly relaxed muscle tone within the LES, a shortened esophageal length within the abdominal cavity, insufficient intra-abdominal pressures, and/or from a contributory factor such as a hiatal hernia.
  • Prolonged acid reflux can cause serious complications such as esophagitis, erosions, esophageal bleeding or ulcers. In addition, chronic scarring caused by acid reflux can cause narrowing or stricture in the esophagus. Some patients develop Barrett's esophagus which is a form of severe damage to the esophageal lining. It is believed that Barrett's esophagus is a precursor to esophageal cancer.
  • As many as 20 million American adults suffer from moderate to severe GERD. For chronic GERD and heartburn, a physician may prescribe medications to reduce acid in the stomach, such as H2-blockers (cimetidine, famotidine, nizatidine and ranitidine). Another form of drug therapy utilizes a proton pump inhibitor (PPI) that inhibits an enzyme in the acid-producing cells of stomach from producing acid (omeprezole, lansoprezole). Yet another form of drug therapy includes motility drugs for quickening the emptying of stomach contents (cisipride, bethanechol and metclopramide). The above-described drug therapies will reduce acid reflux thus reducing pain to the patient, but either have no impact on, or even increase alkaline reflux which can cause severe erosions in the esophagus. Further there exists increasing evidence that lifetime drug therapies can result in atrophic gastritis in certain patients, which is known precursor to Barrett's esophagus.
  • Since GERD us caused by an anatomic (mechanical) defect, certain surgeries are well suited to correct the defect by effectively lengthening the LES and/or increasing intraluminal pressures within the LES to prevent acid reflux. The leading surgical procedure is an endoscopic Nissen fundoplication, in which the surgeon develops a fold (plication) in the fundus of the stomach and then wraps and sutures the plication generally around the LES to increase intra-esophageal pressures therein. An endoscopic Nissen fundoplication is difficult to perform and typically requires the use of several disposable surgical instruments that are expensive. An open surgery to accomplish a Nissen fundoplication also is possible but undesirable because it requires lengthy postoperative recuperation and results in a long disfiguring upper abdominal incision.
  • There is therefore a need for a new therapies for treating GERD that offer mechanical or biomechanical solutions to the anatomic defect that underlies gastro-esophageal reflux. Preferably, such new approaches to alleviate acid reflux will not rely on lifetime drug therapies which do not correct the anatomic defect causing acid reflux.
  • OBJECTS AND SUMMARY OF THE INVENTION
  • The principal objects of this invention are to provide instruments and techniques for least invasive delivery of thermal energy through a tissue surface to a targeted tissue volume to accomplish the controlled remodeling of the treated tissue, and may also be referred to as bulking tissue. The targeted tissues that can be treated in a “least invasive” manner include, but not limited to, soft tissues in the interior of a body (in particular, collagenous tissues such as fascia, ligamentous tissue), collagen-containing walls of vessels and organs, and anatomic structures having, supporting or containing an anatomic lumen (e.g., esophagus, urethra) Such tissues hereafter may be referred to as “targeted” tissue volumes or “target sites”.
  • More particularly, the invention discloses techniques and instruments that utilize radiofrequency (Rf) energy delivery to selectively injure cells and extracellular compositions (e.g., proteins) in a target site to induce a biological response to the injury—such biological response including cell reproduction to an extent but more importantly the population of the extracellular space with collagen fibers in a repair matrix. Thus, the controlled alteration or modeling of the structural and mechanical characteristics of a targeted tissue site is possible by synthesis of new collagen fibers (or “bulking effects”) therein. The above-described objects of the invention are enhanced by controlled manipulation of certain bio-physical characteristics of the target tissue prior to the delivery of Rf energy to induce the injury healing process. Besides the synthesis of collagen matrices, another object of the invention is the acute shrinkage of native collagen fibers in the targeted tissue volume. Such acute collagen shrinkage can cause tightening of a targeted tissue volume.
  • The injury healing process in a human body is complex and involves an initial inflammatory response which in collagenous tissues is followed by a subsequent response resulting in the population of new (nascent) collagen in the extracellular space. A mild injury may produce only an inflammatory reaction. More extensive tissue trauma invokes what is herein termed the injury healing response. Any injury to tissue, no matter whether mechanical, chemical or thermal may induce the injury healing response and cause the release of intracellular compounds into the extracellular compartment of the injury site. This disclosure relates principally to induction of the injury healing process by a thermally-mediated therapy. The temperature required to induce the response ranges from about 40° C. to 70° C. depending on the targeted tissue and the duration of exposure. Such a temperature herein may be referred to as Tncs (temperature that causes “new collagen synthesis”). The temperature needed to cause such injury and collagen synthesis is lower than the temperature Tsc (temperature for acute “shrinkage of collagen”) in another modality of the method of the invention disclosed herein.
  • In order to selectively injure a target tissue volume to induce the population of the extracellular compartment with a collagen matrix, “control” of the injury to a particular tissue is required. In this disclosure, a Rf energy source is provided to selectively induce the injury healing process. (It should be appreciated that other thermal energy devices are possible, for example a laser). In utilizing an Rf energy source, a high frequency alternating current (e.g., from 100,000 Hz to 500,000 Hz) is adapted to flow from one or more electrodes into the target tissue. The alternating current causes ionic agitation and friction in the targeted tissue as the ions follow the changes in direction of the alternating current. Such ionic agitation or frictional heating thus does not result from direct tissue contact with a heated electrode.
  • In the delivery of energy to a soft tissue volume, I=E/R where I is the intensity of the current in amperes, E is the energy potential measured in volts and R is the tissue resistance measured in ohms. In such a soft tissue volume, “current density” or level of current intensity is an important gauge of energy delivery which relates to the impedance of the tissue volume. The temperature level generated in the targeted tissue volume thus is influenced by several factors, such as (i) Rf current intensity (ii) Rf current frequency, (iii) tissue impedance levels within the targeted tissue volume, (v) heat dissipation from the targeted tissue volume, (vi) duration of Rf delivery, and (vii) distance of the targeted tissue volume from the electrodes. A subject of the present invention is the delivery of “controlled” thermal energy to a targeted tissue volume with a computer controlled system to vary the duration of current intensity and frequency together, based on sensor feedback systems.
  • In the initial cellular phase of injury healing, granulocytes and macrophages appear and remove dead cells and debris. In the inflammation process, the inflammatory exudate contains fibrinogen which together with enzymes released from blood and tissue cells, cause fibrin to be formed and laid down in the area of the tissue injury. The fibrin serves as a hemostatic barrier and thereafter acts as a scaffold for repair of the injury site. Fibroblasts migrate and either utilize the fibrin as scaffolding or for contact guidance thus further developing a fiber-like scaffold in the injury area. The fibroblasts not only migrate to the injury site but also proliferate During this fibroplastic phase of cellular level repair, a extracellular repair matrix is laid down that is largely comprised of collagen. Depending on the extent of the injury to tissue, it is the fibroblasts that synthesize the collagen within the extracellular compartment as a form of connective tissue (hereafter nascent collagen), typically commencing about 36 to 72 hours after the injury.
  • Thus, in the injury healing response, compound tissues or organs are repaired by such fibrous connective tissue formation (or matrix formation). Such fibrous connective tissue is the single most prevalent tissue in the body and gives structural rigidity or support to tissues masses or layers. The principal components of such connective tissues are three fiber-like proteins-collagen, reticulin and elastin along with a ground substrate. The bio-mechanical properties of fibrous connective tissue and the repair matrix are related primarily to the fibrous proteins of collagen and elastin. As much as 25% of total body protein is native collagen. In repair matrix tissue, it is believed that nascent collagen is in excess of 50%.
  • The unique properties of collagen are well known. Collagen is an extracellular protein found in connective tissues throughout the body and thus contributes to the strength of the musculo-skeletal system as well as the structural support of organs. Numerous types of collagen have been identified that seem to be specific to certain tissues, each differing in the sequencing of amino acids in the collagen molecule.
  • It has been previously recognized that collagen (or collagen fibers as later defined herein) will shrink or contract longitudinally when elevated in temperature to the range of 60° C. to 80° C., herein referred to as Tsc. Portions of this disclosure relate to techniques for controlled shrinkage of collagen fibers in the soft tissue, and more generally to the contraction of a collagen-containing tissue volume, (including both native collagen and nascent collagen) for therapeutic purposes.
  • Collagen consists of a continuous helical molecule made up of three polypeptide coil chains. Each of the three chains is approximate equal length with the molecule being about 1.4 nanometers in diameter and 300 nm. in length along its longitudinal axis in its helical domain domain (medial portion of the molecule). The spatial arrangement of the three peptide chains in unique to collagen with each chain existing as a right-handed helical coil. The superstructure of the molecule is represented by the three chains being twisted into a left-handed superhelix. The helical structure of each collagen molecule is bonded to together by heat labile intermolecular cross-links (or hydrogen cross-links) between the three peptide chains providing the molecule with unique physical properties, including high tensile strength along with moderate elasticity. Additionally, there exist heat stabile or covalent cross-links between the individual coils. The heat labile cross-links may be broken by mild thermal effects thus causing the helical structure of the molecule to be destroyed with the peptide chains separating into individual randomly coiled structures. Such thermal destruction of the cross-links results in the shrinkage of the collagen molecule along its longitudinal axis to up to one-third of its original dimension, in the absence of tension.
  • A plurality of collagen molecules (also called fibrils) aggregate naturally to form collagen fibers that collectively make up the a fibrous matrix. The collagen fibrils polymerize into chains in a head-to-tail arrangement generally with each adjacent chain overlapping another by about one-forth the length of the helical domain a quarter stagger fashion to form a collagen fiber. Each collagen fiber reaches a natural maximum diameter, it is believed because the entire fiber is twisted resulting in an increased surface are that succeeding layers of fibrils cannot bond with underlying fibril in a quarter-stagger manner.
  • Thus, the present invention is directed to techniques and instruments for controlled thermal energy delivery to portions of a patient's LES, in alternative therapies, either:
  • a) to selectively injury cells and proteins in walls of the LES to induce an injury healing response which populates the extracellular compartment with a collagen fiber matrix (“nascent collagen”) to bulk and alter the architecture and flexibility characteristics of tissue volumes within walls of the LES; or
  • b) to, optionally, shrink either “native” collagen or “nascent” collagen in tissue volumes within the wall of the LES to further alter mechanical characteristics of the LES and increase intra-esophageal pressures.
  • More in particular, the device of the present invention for “modeling” a collagen matrix in targeted tissue (or “bulking” targeted tissue) in walls of the patient's LES is fabricated as a flexible bougie that carries thermal energy delivery means in its distal working end. Typically an Rf source is connected to at least one electrode carried in the working end. The working end may carry a single electrode that is operated in a mono-polar mode or a plurality of electrodes operated in either a mono-polar or bi-polar manner, with optional multiplexing between various paired electrodes. A sensor array of individual sensors also is carried in the working end, typically including (i) thermocouples and control circuitry, and/or (ii) impedance-measuring circuitry coupled to the electrode array.
  • A computer controller is provided, together with the feedback circuitry from the sensor systems, that is capable of full process monitoring and control of: (i) power delivery; (ii) parameters of a selected therapeutic cycle, (iii) mono-polar or bi-polar energy delivery, and (iv) multiplexing Rf delivery. The controller also can determine when the treatment is completed based on time, temperature, tissue impedance or any combination thereof.
  • In a first method of the invention, the device is introduced through the patient's mouth until the working end and electrode array is positioned within the LES. The therapeutic phase commences and is accomplished under various monitoring mechanisms, including but not limited to (i) direct visualization, (ii) measurement of tissue impedance of the target tissue masses relative to the device, and (iii) utilization of ultrasound imaging before or during treatment. The physician actuates the pre-programmed therapeutic cycle for a period of time necessary to elevate the target tissue mass to Tncs (temperature of new collagen synthesis) which is from 45° to 60° depending on duration of energy delivery.
  • During the therapeutic cycle, the delivery of thermal energy is conducted under full-process feedback control. The delivery of thermal energy induces the injury healing response which thereafter populates the mass with an extracellular collagen matrix and reduces the flexibility of the LES over the subsequent several days and weeks. The physician thereafter may repeat the treatment.
  • In a second method of the invention, (either the initial or a subsequent therapeutic cycle) the delivery of Rf energy may be elevated to shrink collagen fibers at a range between 60° to 80° C. to reach Tsc. The effect of such collagen shrinkage is to rigidify or bulk the treated tissue volumes in the wall of the LES.
  • Following an initial therapeutic cycle, the treatment can be repeated until the desired increase in intra-esophageal pressures is achieved. It is believed that such periodic treatments (e.g., from 2 to 6 treatments over a period of several weeks) may be best suited to treat the LES.
  • The above-described modalities of (i) induced synthesis of collagen in collagenous tissues, and (ii) shrinkage of collagen in collagenous tissues describe the effects on LES tissue volumes. These methods of treating the LES are defined herein by a particular temperature range that causes the exact cellular/extracellular effects in the targeted tissue volumes, and are intended to be inclusive of other descriptive terms that may be used to more generally characterize treatments, such as tightening tissue, bulking tissue, fusing or fusion of collagenous tissues, creating scar tissue, sealing or welding collagen-containing tissue, shrinking tissue and the like. The methods disclosed herein are not defined to include ablating tissue, which occurs at higher temperature levels.
  • In general, the present invention advantageously provides least invasive thermally-mediated techniques for increasing intraluminal pressures in a patient's LES to prevent gastro-esophageal reflux.
  • The present invention provides novel devices and techniques for thermally inducing an injury healing response to alter cellular/extracellular architecture in the LES.
  • The present invention provides techniques for thermal induction of bulking of tissue volumes around a sphincter in an anatomic lumen.
  • The present invention advantageously provides an electrode array fur delivering a controlled amount of Rf energy to a specific targeted tissue volume in the LES having a particular shape or pattern.
  • The present invention provides an electrode array for delivering a controlled amount of Rf energy to a specific target collagen-containing tissue volume to achieve a controlled contraction of the collagen fibers therein.
  • The present invention provides a novel device and technique for contraction of collagen fibers around the lumen of an anatomic structure to reduce the dimension of the lumen.
  • The present invention also provides an instrument and method in which a bougie-type member has a working channel to accommodate an endoscope, an accessory instrument or for therapeutic agent delivery or suction.
  • The present invention advantageously provides a device that is inexpensive and disposable. Additional advantages and features of the invention appear in the following description in which several embodiments are set forth.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a perspective view of a Type “A” device and Rf energy source of the present invention.
  • FIG. 2 is transverse sectional view of the device of FIG. 1 taken along line 2-2 of FIG. 1.
  • FIG. 3A is an enlarged perspective view of the working end of the device of FIG. 1.
  • FIG. 3B is transverse sectional view of the working end of FIG. 3A taken along line 3B-3B of FIG. 3A.
  • FIG. 4 is a perspective view of an alternative embodiment of working end similar to FIG. 3A.
  • FIGS. 5A-5F are views of a portion of the wall of a lower esophageal sphincter (LES) showing various patterns of thermally-mediated treatments developed by various electrode arrays.
  • FIG. 6A is a view of an alternative embodiment of working end similar to that of FIG. 3A.
  • FIG. 6B is an alternative embodiment of working end showing a working channel.
  • FIG. 6C is a block diagram of the Rf source of the invention including a computer controller.
  • FIGS. 7A-7D are schematic views of a method of thermally-mediated treatment of the LES utilizing the device of FIG. 1; FIG. 7A being a view of positioning the working end in the region of the LES; FIG. 7B being a view of expansion of an optional balloon carried at the working end; FIG. 7C being a view of sectional view of the working end taken along line 7C-7C of FIG. 7B showing the targeted tissue region; and, FIG. 7D showing the tissue dimensions following a thermally mediated therapy.
  • FIGS. 8A-8B are views of the working end of a Type “B” of device for thermally-mediated therapies of the LES and its means of capturing the wall of the LES for treatment.
  • FIG. 9 is a view of the working end of an alternative Type “B” devices similar to the device FIGS. 8A-8B.
  • FIG. 10 is a view of a portion of the wall of the LES showing a method of treatment with a Type “B” device.
  • FIG. 11A is a view of the working end of another alternative Type “B” with rolling components.
  • FIG. 11B is a view of a portion of the wall of the LES showing a method of treatment with the working end of FIG. 11A.
  • FIG. 12A is a view of the working end of yet another Type “B” device.
  • FIG. 12B is a view of a portion of the wall of the LES showing a method of treatment with the working end of FIG. 12A.
  • FIG. 13A is a view of a Type “C” device system for thermally-mediated treatments of the LES.
  • FIG. 13B is a view of the working end of a component of the Type “C” system of FIG. 13A. FIG. 13C is a views of an alternative working end similar to that of FIG. 13B.
  • FIG. 14 is a view of the wall of the LES showing a method of treatment with the Type “C” system of FIG. 13A.
  • FIG. 15 is a view of the working end of another Type “C” device
  • DESCRIPTION OF THE PREFERRED EMBODIMENT OF THE INVENTION
  • 1. Type “A” Device for Thermally-Mediated LES Therapy.
  • By way of example, FIG. 1 depicts LES treatment device 5 that is to be utilized for a thermally-mediated alteration of the cellular/extracellular architecture of a lower esophageal sphincter (LES) while at the same time sizing or gauging the lumen of the esophagus. More in particular, device 5 comprises elongate extension member 10 with proximal end 11 and working end 15 with distalmost tip 16. Referring to FIGS. 1 and 2, extension member 10 has a generally cylindrical shape along longitudinal axis 17 with an overall length of approximately 60 to 90 centimeters. The cross-sectional dimension of extension member 10 would typically range in diameters from #40 to #60 French for various patients having varied esophageal anatomies (but may be much smaller as described below for introduction through a working channel of a flexible gastroscope).
  • The extension member 10 preferably is capable of bending in an approximately 1.0 cm. radius (or less) and may comprise a flexible plastic casing 18 with a high-density liquid, gel or other suitable flexible core 19 inside the casing and the tapered tip. The device may compare in size and flexibility to a commercially available bougie that is adapted to push through an esophagus to enlarge the lumen, such as a bougie manufactured by Pilling Weck, 420 Delaware Drive, Fort Washington, Pa.
  • In this Type “A” variant, an Rf energy source 40 is provided for delivering thermal energy to portions of the LES. The Rf energy source 40 may alternatively be replaced with a microwave source, or another known source of thermal energy such as a laser. It further should be appreciated that other sources of energy such as ultrasound or high-energy focused ultrasound (HIFU) that are known in the art may be utilized to cause thermally-mediated treatments of target sites in the LES. The Rf energy source 40 is detachably connected to extension member 10 by power cable 42.
  • Referring to FIG. 3A, the working end 15 carries at least one electrode in an electrode array 44, and preferably carries a plurality of Rf electrodes 45 a-45 n that are positioned in the surface 46 of working end 15. FIGS. 1 and 3A show two exemplary electrodes 45 a-45 b arranged longitudinally in extension member 10 in a spaced relationship in surface 46. The electrodes 45 a-45 b shown in FIG. 3 may be operated in a mono-polar mode (with groundplate) but preferably are operated in a bi-polar mode to provide controlled energy delivery to achieve a particular temperatures between the adjacent paired electrodes 45 a-45 b in the wall W of the LES proximate to the electrodes. The electrodes are of any suitable biocompatible conductive material which conduct current to and from tissue around the LES in direct contact with electrodes 45 a-45 b.
  • Expansion means are preferably (but optionally) carried in working end 15 for increasing the transverse dimension of the working portion and for pressing any electrodes 45 a-45 n securely against a wall of the lumen of the LES. Inflatable balloon 50 is capable of collapsed and inflated conditions and is depicted in FIG. 1 (phantom view of inflated condition) and FIGS. 3A and 3B in an inflated condition. Balloon 50 is incorporated into the wall of extension member 10 in this embodiment generally on the opposite side from electrodes 45 a-45 b. Balloon 50 preferably is made of an elastomeric material, for example silicone or latex and has chamber 52 that is inflatable to a maximum transverse dimension of approximately 10 to 30 millimeters at low pressures (e.g., from 0.5 to 5 psi). A Luer-type fitting 53 is coupled to tube 54 that is provided in core 19 of extension member and communicates with an inflation source to inflate balloon 50, for example a syringe with saline solution or air (FIG. 1). It should be appreciated that the expansion means of the invention is shown as balloon 50 but such expansion means also may comprise any type of suitable mechanical expansion structure disposed within the core of working end 15 that is adapted to expand the cross-section of the working portion that is known in the art (e.g., flexible ribs that are actuated with a pull cable).
  • Visible and/or radiopaque and markings 57 are shown in FIG. 1 and are used to both angularly and axially position the working end 15 of the device within the patient's LES. The markings 57 in the proximal portion of extension member 10 are useful to the anesthesiologist or physician's assistant to gauge the depth of insertion of the device as well as its rotational angle.
  • As shown in FIG. 3A, this particular embodiment of device 5 has electrodes 45 a-45 b each with an elongate shape with the electrodes being longitudinally oriented in relation to axis 17 of extension member 10. Preferably, the electrodes 45 a and 45 b have a length ranging from about 5.0 mm. to 15.0 mm. and a width ranging from 0.25 mm. to 2.5 mm. The spacing dimension d between the electrodes may range from about 0.5 mm. to 10.0 mm.
  • Although FIGS. 3A-3B show a variant of device 5 with two electrodes 45 a and 45 b, it should be appreciated that a plurality of greater than two electrodes may be carried in particular spaced relationships along working end 15, as shown in FIG. 4. In FIG. 4, the alternative embodiment is shown with six longitudinal electrodes 45 a-45 f. The embodiment of FIG. 4 thus may be operated in a mono-polar mode or in a bi-polar mode with a computer controller 60 (see FIG. 1) operatively connected to the Rf source 40 and electrodes and temperature sensors to multiplex (of vector) the current flow between and among various paired electrodes. (It should be appreciated that working end 15 may carry only a single electrode operated in a mono-polar mode and fall within the scope of the invention).
  • In the preferred embodiment described above, the elongate configuration of the electrodes and their longitudinal orientation was selected because it is believed that Rf energy delivery to elongate regions of the LES will prove optimal to accomplish the objectives of methods of the invention. As will be described below, functional portions of the lower esophageal sphincter extend as much as several cm. from the gastro-esophageal junction and it is believed that the disclosed thermally-mediated treatments of collagen synthesis should extend over a substantial axial dimension of the LES. Still, another the objective may be collagen shrinkage based on anatomic dimensions and motility studies of a particular patient. Further, the diagnosis may indicate that such collagen shrinkage is desired in a localized annular or part annular region. Thus, other electrode patterns in a “Type A” device are possible and fall within the scope of the invention to deliver particular patterns of thermally-mediated treatment to the wall W of the LES. FIG. 5A shows a singular annular (circumferential) pattern of treated tissue indicated at T in the wall W of a lower esophageal sphincter to shrink collagen and slightly reduce the dimension of the lumen by creating bulk in region T. In FIGS. 5A-5F, treated tissue patterns are shown in portions of wall W (member 10 in phantom view) and it can be understood that electrodes may be of particular configuration to deliver such treatment locations and patterns. (E.g., a single electrode operated in a mono-polar mode (with groundpad) can develop the targeted treatment band T of FIG. 5A, or two parallel electrodes operated in a bi-polar mode may cause the targeted treatment band T of FIG. 5A by energy flow therebetween). FIG. 5B shows multiple annular regions or bands of treated tissue T. FIG. 5C illustrates a multiplicity of treatment regions T as when the objective is the delivery of Rf energy in a diffuse manner over a substantial portion of wall W. FIG. 5D illustrates a plurality of helical treatment regions T which would result in diffuse effects if the regions were close together. FIG. 5E illustrates a v-shaped or chevron-shaped treatment regions T. FIG. 5F is a more greatly enlarged view of wall W with treated regions T multiple electrodes 45 a-45 n in phantom view. FIG. 5F shown various arrows A that indicate multiplexed vectors of current delivery are possible to cause the thermally-mediated treatments of regions T. Any of the elongate electrodes of FIG. 5A-5E may be configured as multiple intermittently-spaced electrodes and optionally may operate in a bi-polar and multiplexed mode with varied possible vectors between various paired electrodes. Only certain electrodes may delivery current, all for a controlled periods of time. The multiplexer also may cause the Rf energy delivery to switch between mono-polar and bi-polar during a treatment.
  • In the embodiments shown, the electrodes are of any suitable conductive material which is adapted to deliver Rf energy to soft tissue in the walls W of the LES around the esophageal lumen without ablating (and necrosing) any surface tissue to significant degree. The electrode material may include gold, nickel titanium, platinum, stainless steel, aluminum and copper. Each individual electrode of the array is connected to Rf source 40 and controller 60 by a suitable current-carrying wires 61 a-61 n within introducer member 10. The proximal portions of such current-carrying wires are carried in power cable 42 that connects with Rf source 40.
  • Referring back to FIG. 3A it can be seen that a sensor array of individual sensors 65 a-65 b (an number of sensors are possible) also is provided in a spaced relationship around working end 15. The sensor array will typically include thermocouples or thermisters to measure temperature levels of an electrode or of a portion of the wall W in contact with the sensor. Further, the sensor array includes impedance sensing capabilities (not shown) that measures tissue impedance in a conventional manner between particular electrode elements at the controller 60 as described below. Current-carrying wires 66 a-66 b are shown in FIGS. 2-3A are connected to sensors 65 a-65 b. Other wires (not shown) may be provided in the device that could be dedicated specifically to measuring tissue impedance. One or more such impedance monitoring systems may be used to confirm prior to the therapeutic cycle that a satisfactory coupling of energy will be accomplished. Impedance is monitored between each electrode and a groundpad when operated in a mono-polar mode, or between various electrodes when operated in a bi-polar mode.
  • Another embodiment of a Type “A” device 5 is shown in FIG. 6A wherein an ultrasound source 70 may be coupled to one or more ultrasound transducers 72 (collectively) in a spaced relationship in working end 15 of extension member 10. An output of ultrasound source 70, optionally in combination with Rf source 40, any be adapted to deliver thermal energy to the LES. Each ultrasound transducer 72 may be a piezoelectric crystal mounted on a suitable substrate. A conventional ultrasound lens of electrically insulated material is fitted between the exterior of surface 18 of working end 15 and the piezoelectric crystal which is connected by electrical leads in extension member to ultrasound source 70. Each ultrasound transducer thus is capable of transmitting ultrasound energy into the target tissue of the LES for imaging purposes or high-energy ultrasound (HIFU) to deliver thermal energy. Thermocouples can provide accurate temperature measurements of surface temperatures at various points along the esophageal lumen. Such thermal sensors are preferably adjacent to piezoelectric crystals.
  • FIG. 6B shows another embodiment of device 5 with a working channel 76, with an open proximal end in the proximal end 11 of the device with a distal termination (not shown) at the distal end of the device. The working channel 76 may be any suitable dimension, for example from about 0.5 mm. to 5.0 mm. or more, to accommodate a flexible shaft accessory instrument (e.g., an endoscope or forceps). Working channel 76 also may be utilized to deliver therapeutic agents to the patient's stomach or to suction air or liquid secretions from the stomach.
  • Referring now to FIG. 6C, a block diagram of the Rf source 40 and controller 60 is shown. The controller 60 includes a CPU coupled to the Rf source and multiplexer 80 through a bus. Associated with the controller system may be a keyboard, disk drive or other non-volatile memory system, along with displays that are known in the art for operating such a system. The operator interface may include various types of imaging systems for observing the treatment such as thermal or infrared sensed displays, ultrasonic imaging displays or impedance monitoring displays. The multiplexer 80 is driven by controller 60 (digital computer) which includes appropriate software 82.
  • In operation, current supplied to individual electrodes 45 a-45 n along with voltage may be used to calculate impedance. Thermocouples 65 carried in a position proximate to the electrodes together with additional thermal sensors positioned within the Rf source or generator are adapted to measure energy delivery (current and voltage) to each electrode at the site of targeted tissue during a therapeutic cycle. The output measured by thermal sensors is fed to controller 60 in order to control the delivery of power to each electrode location. The controller 60 thus can be programmed to control temperature and Rf power such that a certain particular temperature is never exceeded at a targeted treatment site. The operator further can set the desired temperature which can be maintained. The controller 60 has a timing feature further providing the operator with the capability of maintaining a particular temperature at an electrode site for a particular length of time. A power delivery profile may be incorporated into controller 60 as well as a pre-set for delivering a particular amount of energy. A feedback system or feedback circuitry can be operatively connected to the impedance measuring system, and/or the temperature sensing system or other indicators and to the controller 60 to modulate energy delivery at Rf source 40.
  • The controller software and circuitry, together with the feedback circuitry, thus is capable of full process monitoring and control of following process variables: (i) power delivery; (ii) parameters of a selected treatment cycle (time, temperature, ramp-up time etc.), (iii) mono-polar or bi-polar energy, and (iv) multiplexing between various electrode combinations. Further, controller 60 can determine when the treatment is completed based on time, temperature or impedance or any combination thereof. The above-listed process variables can be controlled and varied as tissue temperature is measured at multiple sites in contact with the sensor array, as well as by monitoring impedance to current flow at each electrode which indicates the current carrying capability of the tissue during the treatment process. Controller 60 can provide multiplexing along various vectors as previously described, can monitor circuit continuity for each electrode and can determine which electrode is delivering energy.
  • In FIG. 6C, the amplifier 85 is a conventional analog differential amplifier for use with thermisters and transducers. The output of amplifier 85 is sequentially connected by analog multiplexer 80 to the input of analog digital converter 86. The output of amplifier 85 is a particular voltage that represents the respective sensed temperatures. The digitized amplifier output voltages are supplied to microprocessor 88. Microprocessor 88 thereafter calculates the temperature and/or impedance of the tissue site in question. Microprocessor 88 sequentially receives and stores digital data representing impedance and temperature values. Each digital value received by microprocessor corresponds to a different temperature or impedance at a particular site.
  • The temperature and impedance values may be displayed on operator interface as numerical values. The temperature and impedance values also are compared by microprocessor with programmed temperature and impedance limits. When the measured temperature value or impedance value at a particular site exceeds a pre-determined limit, a warning or other indication is given on operator interface and delivery of Rf energy to a particular electrode site can be decreased or multiplexed to other electrodes. A control signal from the microprocessor may reduce the power level at the generator or power'source, or de-energize the power delivery to any particular electrode site. Controller 60 receives and stored digital values which represent temperatures and impedance sent from the electrode and sensor sites. Calculated skin surface temperatures may be forwarded by controller 60 to display and compared to a predetermined limit to activate a warning indicator on the display.
  • 2. Method of Use of Type “A” Device.
  • Operation and use of the instrument shown in FIG. 1 (with two electrode 45 a-45 b embodiment) in performing the method of the present invention can be described briefly as follows (FIGS. 7A-7D). The physician or an assistant introduces working end 15 of device 5 through the patient's mouth into lumen 100 of esophagus 102. Referring to FIG. 7A, the physician advances extension member 10 distally and rotationally until working end 15 and electrodes 45 a and 45 b are in a suitable position within the LES (see FIG. 7A). The physician also may advance and turn the instrument to a correct angle by reference to markings 57 on the proximal portion of the device (see FIG. 1). In the illustrations, it is assumed that the targeted tissue is in a quadrant at the patient's left side or at the anterior of the LES (see FIGS. 7A-7B). It is believed the area of treatment will vary from patient to patient as determined by motility studies and anatomic characteristics, and probably most cases will involve treatments in several angular positions within the LES.
  • Referring to FIG. 7B, the diameter of extension member 10 may fit somewhat loosely or snugly in esophageal lumen 100 depending on the diameter of device selected. As shown in FIG. 7C, the physician preferably (but optionally) inflates balloon 50 with an inflation medium, for example air or saline solution from a syringe (not shown). Balloon 50 is inflated to a sufficient dimension to press the surface of working end 15, and more particularly electrodes 45 a and 45 b, into firm contact with surface 104 of targeted tissue in wall W of the LES. (It should be appreciated that a flexible fiberscope 105 (phantom view) may introduced through a optional working channel 76 to view the gastro-esophageal junction 108 from inside the patient's stomach 110 which may be useful in positioning the device (see FIG. 7B)). The physician selects the treatment site based on anatomical knowledge of the LES and is thus capable of avoiding thermal energy delivery to certain areas or sides of the LES if so desired.
  • Now referring to FIG. 7B, the physician commences the therapeutic phase of Rf delivery under various monitoring mechanisms, including but not limited to, (i) measurement of tissue impedance of the target tissue to determine electrical conductivity between the targeted tissue and the electrode arrangement of device 5, (ii) utilization of ultrasound imaging before and/or during treatment to establish a baseline and duty-cycle tissue characteristics for comparative measurements; and optionally (iii) direct visualization via a fiberscope introduced through a working channel into the stomach and articulated (FIG. 7B). Alternatively, a small diameter flexible scope could be positioned within lumen 100 to view the location of working end 15. (Another similar alternative of delivering the thermally-mediated treatment disclosed herein is to have a small diameter extension member 10 (e.g., 2.0 mm, to 6.0 mm.) that can be introduced through the working channel of a flexible scope). All these approaches are similar and can yield the same results in the targeted tissue.
  • Still referring still to FIG. 7B, the physician may actuate the controller to perform a first modality of treatment described above as a collagen synthesis modality. The controller actuates a pre-programmed therapeutic cycle for a period of time necessary to elevate the targeted tissue T to a particular time/temperature range based on feedback from the sensor system. The cycle can elevate temperatures in the tissue to a range between 40° C. to 70° C. for a period of time ranging from 60 seconds to 10 minutes. More preferably, the therapeutic cycle would elevate temperatures in wall W of the LES to a range between 45° C. and 65° C. for a period of time ranging from 60 seconds to 5 minutes. Still more preferably, the therapeutic cycle would include temperatures in a range between 50° C. and 60° C. for a period of time ranging from 60 seconds to 3 minutes. At the particular selected parameters, the thermal effects will selectively injures cells in and below the surface 104 of wall W at target sites T thus inducing the desired injury healing response. The depth of thermal penetration into the target tissue sites T is determined by the current intensity and duration, and most importantly the thermal relaxation time of the tissue, to preferably effect selective heating of tissue at a depth of about 0.5 mm. to 2.5 mm. from the surface 104 of the wall W of the lumen 100.
  • As can be seen in FIG. 7C, electrodes 45 a and 45 b are in direct contact with tissue surface 104 of wall W along the tissue-electrode interface. Preferably, the controller 60 will sense temperatures along the tissue-electrode interface by means of the sensor array and/or impedance monitoring system and maintain temperature at the tissue surface 104 at a level below that which ablate the surface, generally by lowering the current intensity or making the energy delivery intermittent. The effect of elevating the temperature of the interior of wall W of the LES without surface ablation can be accomplished because of surface cooling caused by conduction of heat into lumen 100 and the heat-absorbing (heat-sink) characteristics of the working end 15 and extension member 10.
  • During the therapeutic cycle, the delivery of energy is preferably conducted under full-process feedback control, and in fact the treatment phase may require little attention by the physician ft should be appreciated that the target tissue can be treated uniformly, or various discrete portions of the target tissue can be treated selectively. (In embodiments with a greater number of electrodes, different levels of current can be delivered to different electrode elements, or current can be multiplexed through various electrodes along different vectors as described previously).
  • A follow-on portion of the therapeutic cycle may comprise a diagnostic phase to gauge the success of the treatment. With energy delivery terminated, diagnosis may be accomplished through (i) direct visualization, (ii) ultrasound imaging, (iv) infrared imaging, or (v) temperature measurements.
  • Following such a therapeutic cycle to cause collagen synthesis or bulking of target tissue portions around the LES, the patient can return to normal activities with periodic monitoring of the intra-esophageal pressure of the LES as well as muscle response of the LES in conventional motility studies. Thereafter, the same treatment may be repeated until alterations in cellular/extracellular architecture increases intraluminal pressures within the LES to the desired level. It is believed that periodic treatments (e.g., 1 week to 2 weeks between treatments) is best suited to alter the mechanical characteristics of the LES. The thermally-mediated treatment induces a bodily response which includes populating the targeted tissue sites T with nascent collagen in the extracellular spaces, which after periodic treatments will make walls W of the LES to be bulked up or thicker and which will cause a reduced cross-section of lumen 100 within the LES.
  • If the physician elects to tighten the LES to a greater extent, he may in an initial treatment or in subsequent treatment, perform a different modality of thermally-mediated treatment described above as the collagen shrinkage modality. In this case, the physician elects to deliver elevated levels of Rf energy to contract or shrink collagen fibers to further tighten or reduce the flexibility of target tissue T within wall portions of the LES. The delivery of Rf energy will shrink collagen fibers as described above in the LES without significant modification of adjacent tissue volumes. The temperature gradients described above can be accomplished to achieve the temperature to contract collagen fibers in the targeted tissue without increasing the temperature of the surface 104 so that the surface tissue will not be ablated, blistered or necrosed. The energy level is monitored and controlled as to each individual electrode as detailed above by controller 60. The energy delivery is continuously changed based on sensor inputs which includes temperature data and impedance data from the sensors provided in the device.
  • In the collagen shrinkage modality of treatment, a pre-programmed therapeutic cycle is selected to achieve shrinkage of native collagen. In this case, the delivery of energy is controlled to elevate temperatures in target tissue T to a range generally between 60° C. to 80° C. Preferably, the therapeutic cycle can be controlled to attain temperatures in the targeted tissue in a range from 60° C. and 70° C. for a period of time ranging from 60 seconds to 5 minutes. Immediate acute longitudinal shrinkage of collagen fibers and molecules will occur in such a temperature range. Thus, the targeted tissue T shrink generally in the direction of collagen fibers therein and will make the walls around the lumen of the esophagus somewhat tighter and resistant to radial extension (opening). Looking at the thermally-mediated effects on such collagenous tissue from a different perspective, the collagen fibers and molecules are increased greatly in caliber, as described above, thus causing a bulking up of the targeted tissue in the LES (see FIG. 7D). In other words, the native collagen (and collagen matrices) will bulk up and tighten the targeted tissue sites T as shown in FIG. 7D. If the therapy is performed following a prior collagen synthesis treatment at the lower temperature ranges described above, the follow collagen shrinkage therapy can be enhanced since both the nascent and native collagenous tissue will shrink within the target tissue sites T. Each subsequent treatment not only will populate the tissue sites T with additional nascent collagen fibers, but also shrinks the nascent collagen fibers from the prior treatment or treatments.
  • 3. Type “B” Device for Thermally-Mediated LES Therapy.
  • By way of example, FIGS. 8A-8B and 9 depict an alternative type of LES treatment device that may be utilized for Rf energy delivery to wall portions W of the LES to alter its cellular/extracellular architecture. More in particular, the system includes an embodiment of elongate device or member 205 with a medial extending portion 206 that is substantially similar to the Type “A” device described above, and elements common to both the Type “A” and Type “B” embodiment will be described with the same reference numerals. As shown in FIG. 8A-8B, the working end 215 of this embodiment carries a tissue-engaging means known in the art comprising an openable/closeable arm structure for engaging target tissue in the wall of the LES (Cf. the openable/closeable arm structure of related Provisional Application Ser. No. 60/024,974 filed on Aug. 30, 1996; and follow-on patent application Ser. No. 09/920,291 filed on Aug. 28, 1997, which disclosures are incorporated herein in their entirety by this reference). FIG. 8A shows a longitudinally-oriented arm structure with arm elements 216 a and 216 b that are rotatable around pivots 217 a and 217 b and are optionally covered within a thin flexible sheath 218 that carries longitudinal electrodes 245 a and 245 b. FIG. 8B shows that arm elements 216 a and 216 b are articulatable from a proximal handle of the device by cables and articulating means known in the art thereby to capture tissue of wall W therebetween. It should be appreciated that the electrodes may be carried directly on the arm elements without a covering sheath. The sheath, however, is preferred to make the instrument perform similar to a bougie for ease of introduction into a patient's esophagus.
  • Referring to FIG. 9, the elongate device 205 further may include an inflatable collar 220 that can be inflated with any suitable medium, for example air or saline solution from a syringe (not shown). Collar 220 is shown in phantom view in an inflated condition and is position around a distal portion of the device. Collar 220 is sufficiently large to prevent it from passing through GE-junction as the device is lifted proximally and thus may serve as a means of positioning electrodes 245 a and 245 b and the articulating arm elements in the LES.
  • In operation, a portion of the wall of the LES is shown in sectional view in FIG. 10 being captured and engaged by arm elements 216 a and 216 b (phantom view) of working end 215. The sectional view depicts the targeted tissue T as a hatched regions in interiors of the wall W of the LES as when Rf energy is delivered in a bi-polar manner between the paired electrodes (mono-polar flow also is possible). The treatment may be in a single location or repeated in a plurality of locations. In order for the arm elements and sheath 218 to better engage the well of the LES, gripping elements known in the art may be configured in the sheath or arm elements to grip tissue (e.g., penetrating elements; tissue gripping studs, or suction apertures communicating with remote suction source) and are intended be encompassed by the scope of the invention.
  • FIG. 11A illustrates another embodiment of Type “B” device in which roller elements 250 a and 250 b are carried in arm elements 216 a and 216 b to progressively the engage the wall W of the LES and delivery Rf energy between various paired electrodes 245 a-245 n in the roller elements 250 a and 250 b. This manner of Rf energy delivery was disclosed in Provisional Application Ser. No. 60/024,974 filed on Aug. 30, 1996 and follow-on patent application Ser. No. 09/920,291 filed on Aug. 28, 1997, and incorporated therein Provisional Application Ser. No. 60/022,790 filed on Jul. 30, 1996 titled Less Invasive Surgical Instruments and Techniques for Treating Sleep Apnea and Snoring; all of which applications are incorporated herein in their entirety by this reference. (In the earlier disclosures, one of the applications of Rf energy delivery was to model the flexibility of a patient's soft palate by means of collagen synthesis and/or collagen shrinkage therein). FIG. 11B is a sectional view of a small portion of the LES with a wall W engaged between rollers 250 a and 250 b and targeted tissue T receiving Rf energy as described above.
  • Another variant of Type “B” device is shown in FIG. 12A in which articulating arm elements 252 a and 252 b are carried in a manner to engage the wall W of the LES at 90° to the previously described embodiment. In other words, the articulating elements 252 a and 252 b are adapted to capture a portion of wall W treat tissue in a fold around a part of a circumference of the LES rather than in a longitudinal fold described previously. Such a manner of capturing tissue and delivering Rf energy to the wall W of an organ was disclosed in Provisional Application Ser. No. 60/024,974 filed on Aug. 30, 1996 and follow-on patent application Ser. No. 09/920,291 filed on Aug. 28, 1997 (incorporated herein by reference). FIG. 12B is a view of a small portion of the LES with a wall W engaged by articulating elements 252 a and 252 b and further indicating targeted tissue T receiving Rf energy in any of the manners described previously.
  • 4. Type “C” System for Thermally-Mediated LES Therapy.
  • By way of example, FIGS. 13A-13C depict an alternative of LES treatment system that may be utilized for performing the above-described methods of treating a lower esophageal sphincter, but this time with the assistance of a separate device from the exterior of the LES in an endoscopic procedure. At the same time, an intraluminal device is used to size or gauge lumen 100 of the esophagus 102. More in particular, the system includes intraluminal esophageal device 305 which is substantially similar to the Type “A” device described above, and hereafter will have similar elements described with the same reference numerals as used above in the Type “A” device. The intraluminal device 305 further includes an inflatable collar 307 that can be inflated with any suitable medium, for example air or saline solution from a syringe (not shown). Collar 307 is shown in phantom view in an inflated condition and is position around a distal portion of the device. Collar 307 is sufficiently large to prevent it from passing through the GE-junction as the device is lifted proximally as a means of positioning electrodes 45 a-45 n in the LES.
  • Intraluminal device 305 cooperates with extraluminal device 310 also shown in FIG. 13A-13C. The extraluminal device 310 has elongate introducer member with proximal end 310 a and is adapted for introduction in the interior of the body through a cannula (e.g., a 5-20 mm. trocar sleeve) working end 315 is carried in the distal portion of introducer member 310 a and comprises an articulatable of flexible section 320 section that has a esophagus-contacting surface portion 322. The esophagus-contacting portion 322 may be substantially planar (see FIG. 13B) but preferably has an at least partial circumferential receiving surface 323 for fitting closely around the esophagus 102 when intraluminal device 305 is positioned within lumen 100 of the esophagus (see FIG. 13C).
  • As can be seen in FIGS. 13A, the extraluminal device 310 has at least one and preferable a plurality of electrodes 345 a-345 n within working end 315. FIG. 14 shows in a (sectional) perspective view that the electrodes 345 a-345 n of extraluminal device 310 are adapted to cooperate with electrodes 45 a-45 b of intraluminal device 305. In use, the electrodes of the two devices, 305 and 310, preferably are adapted to operate in a bi-polar manner with current passing from the extraluminal device to the intraluminal device or vice versa, or in a bi-polar manner between paired electrodes in the extraluminal member with the intraluminal electrodes not activated but facilitating current flow through wall W (or vice versa). Further, the bi-polar operation of the device may be along a various multiplexed vectors as described previously. The extraluminal device may have all the temperature sensing capabilities, impedance monitoring capabilities, and other feedback capabilities of the Type “A” device described above.
  • Alternatively, another embodiment of extraluminal device may be used to deliver a thermally-mediated treatment as described above, but only from the exterior of the esophagus to targeted tissue in the LES. In some cases, Rf energy delivery only from the exterior of the LES may be preferred because it would then be unnecessary to elevate the temperature of surface 104 or mucous membrane of the esophageal lumen 100. As described above, the exterior approach logically would be performed only when the surgeon needed to endoscopically access the patient's abdominal cavity for other reasons, e.g., to treat a hiatal hernia that sometimes contributes to GERD. Since several ports are necessary to endoscopically correct a hiatal hernia, the use of such an extraluminal instrument would make such a procedure no more invasive. In either a mono-polar or bi-polar operating mode, the intraluminal device may simply be a conventional bougie to “stent” the esophagus while performing the thermally-mediated Rf treatment of the LES from its exterior with device 310. FIG. 14 shows the positioning of the devices 305 and 310 in a manner of practicing a method of the invention The extraluminal device may have an articulatable working end so that the esophagus-contacting portion may be easily oriented to lay against the LES. Such a working end may be hinged or flexible by any suitable means (e.g., a pull wire or reciprocating rod mechanism), with the specific articulation characteristics partly dependent on the location of the port which is used to introduce the device into the patient's body.
  • FIG. 15 depicts another embodiment of LES treatment device 335 that may be utilized for thermally-mediated treatment of the LES from its exterior in an endoscopic procedure. This embodiment of extraluminal device has any suitable closing mechanism for closing the at least two esophagus-contacting portions 336 a and 336 b around the LES and esophagus. Such an embodiment would allow the delivery of thermal energy at least partly around the circumference of the LES, and even entirely around the circumference of the LES if so desired. This embodiment would require that the distal esophagus and LES be mobilized before utilizing the device. Again, this device would find use in cases that require repair of a hiatal hernia wherein mobilization of the distal esophagus is required. As shown in FIG. 15, the two esophagus-contacting portions 336 a and 336 b are actuated by reciprocation of sleeve 340 over cam- type elements 342 a and 342 b.
  • It should be appreciated that the combination of intraluminal and extraluminal devices are preferably indexable by any suitable means, by which is meant that it would be desirable to have electrodes of the intraluminal device and the electrodes of the cooperating extraluminal device maintainable in a particular alignment or registration, both axially and angularly. A preferable means is to provide a fiber optic light source in the intraluminal component of the system that will transilluminate the wall W of the LES, thereby allowing the physician to position markings (or apertures) on the extraluminal device relative to the points of transillumination. The two esophagus-contacting portions of the extraluminal instrument are preferably made of a transparent plastic material.
  • It should be appreciated that the surface 18 of working end 15 may carry cooling means as known in the art, wherein cooling lumens may circulate a coolant fluid within the extension member to maintain the surface 104 of the esophageal lumen 100 at a cooled temperature. Alternatively, the extension member may carry the semiconductor Peltier cooling means disclosed in co-pending U.S. patent application Ser. No. 09/110,065 filed Jul. 3, 1998 titled Semiconductor Contact Lens Cooling System and Technique for Light-Mediated Eye Therapies. It should also be appreciated that variations on the thermally-mediated treatments disclosed herein may be accomplished with penetrating needle-type electrodes in a working end 15 as known in the art that can be actuated from a handle portion of an elongate member although this is not a preferred approach.
  • From the foregoing it can be seen that there are provided techniques and instruments that will selectively accomplish thermally-mediated treatments of targeted collagenous tissues in a patient's LES without substantially necrosing or ablating the surface 104 of the esophageal lumen 100. The device can be utilized to selectively injure cells to induce a biological response to populate target tissue site T with a collagen fiber matrix. The device further can be utilized to contract collagen-containing tissue volumes to reduce the diameter of the lumen of LES. It can be readily understood that such techniques of tissue modeling may be applied to other lumens of other anatomic structures in the body. For example, a treatment for urinary incontinence can be effected to shrink tissue, tighten tissue or rigidify tissue with a collagen matrix around the urethra with a trans-urethral Rf instrument. Similarly, tissues around a patient's soft palates can be treated. Specific features of the invention are shown in some figures and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. While the principles of the invention have been made clear in the exemplary Type “A” through Type “C” versions, it will be obvious to those skilled in the art that modifications of the structure, arrangement, proportions, elements, and materials may be utilized in the practice of the invention, and otherwise, which are particularly adapted to specific environments and operative requirements without departing from the principles of the invention. The appended claims are intended to cover and embrace any and all such modifications, with the limits only of the true purview, spirit and scope of the invention.

Claims (1)

1. A method to treat tissue in a selected wall region of an esophagus comprising the steps of
introducing an elongate member into the esophagus, the elongate member comprising at least one electrode operatively coupled to a source of radiofrequency energy and an inflatable body carried by the elongate member free of physical or electrical contact with the electrode;
inflating the body to stabilize the electrode in physical and electrical contact with the selected wall region, while keeping the body free of physical or electrical contact with electrode; and
delivering radiofrequency energy to the electrode to treat tissue in the selected wall region.
US11/365,943 1998-05-20 2006-03-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease Abandoned US20060149224A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/365,943 US20060149224A1 (en) 1998-05-20 2006-03-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US11/469,816 US7507239B2 (en) 1998-05-20 2006-09-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/368,943 US20090187181A1 (en) 1998-05-20 2009-02-10 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/587,957 US20100042091A1 (en) 1998-05-20 2009-10-15 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/751,803 US20100191237A1 (en) 1998-05-20 2010-03-31 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/325,811 US20120083780A1 (en) 1998-05-20 2011-12-14 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/691,822 US8556952B2 (en) 1998-05-20 2012-12-02 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8606898P 1998-05-20 1998-05-20
US09/222,501 US6740082B2 (en) 1998-12-29 1998-12-29 Surgical instruments for treating gastro-esophageal reflux
US10/780,027 US7008419B2 (en) 1998-05-20 2004-02-17 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US11/365,943 US20060149224A1 (en) 1998-05-20 2006-03-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/780,027 Division US7008419B2 (en) 1998-05-20 2004-02-17 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/587,957 Continuation US7857481B2 (en) 2004-01-30 2005-01-29 Multi-functional traffic signal stick
US11/469,816 Continuation US7507239B2 (en) 1998-05-20 2006-09-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Publications (1)

Publication Number Publication Date
US20060149224A1 true US20060149224A1 (en) 2006-07-06

Family

ID=22832483

Family Applications (9)

Application Number Title Priority Date Filing Date
US09/222,501 Expired - Fee Related US6740082B2 (en) 1998-05-20 1998-12-29 Surgical instruments for treating gastro-esophageal reflux
US10/780,027 Expired - Fee Related US7008419B2 (en) 1998-05-20 2004-02-17 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US11/365,943 Abandoned US20060149224A1 (en) 1998-05-20 2006-03-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US11/469,816 Expired - Fee Related US7507239B2 (en) 1998-05-20 2006-09-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/368,943 Abandoned US20090187181A1 (en) 1998-05-20 2009-02-10 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/587,957 Abandoned US20100042091A1 (en) 1998-05-20 2009-10-15 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/751,803 Abandoned US20100191237A1 (en) 1998-05-20 2010-03-31 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/325,811 Abandoned US20120083780A1 (en) 1998-05-20 2011-12-14 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/691,822 Expired - Fee Related US8556952B2 (en) 1998-05-20 2012-12-02 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/222,501 Expired - Fee Related US6740082B2 (en) 1998-05-20 1998-12-29 Surgical instruments for treating gastro-esophageal reflux
US10/780,027 Expired - Fee Related US7008419B2 (en) 1998-05-20 2004-02-17 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Family Applications After (6)

Application Number Title Priority Date Filing Date
US11/469,816 Expired - Fee Related US7507239B2 (en) 1998-05-20 2006-09-01 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/368,943 Abandoned US20090187181A1 (en) 1998-05-20 2009-02-10 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/587,957 Abandoned US20100042091A1 (en) 1998-05-20 2009-10-15 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US12/751,803 Abandoned US20100191237A1 (en) 1998-05-20 2010-03-31 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/325,811 Abandoned US20120083780A1 (en) 1998-05-20 2011-12-14 Surgical instruments and techniques for treating gastro-esophageal reflux disease
US13/691,822 Expired - Fee Related US8556952B2 (en) 1998-05-20 2012-12-02 Surgical instruments and techniques for treating gastro-esophageal reflux disease

Country Status (1)

Country Link
US (9) US6740082B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070142831A1 (en) * 1998-05-20 2007-06-21 Shadduck John H Surgical Instruments And Techniques For Treating Gastro-Esophageal Reflux Disease
US20110034975A1 (en) * 2006-05-26 2011-02-10 Ferree Bret A Methods and apparatus for repairing and/or replacing intervertebral disc components and promoting healing

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464697B1 (en) * 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6073052A (en) * 1996-11-15 2000-06-06 Zelickson; Brian D. Device and method for treatment of gastroesophageal reflux disease
US9023031B2 (en) 1997-08-13 2015-05-05 Verathon Inc. Noninvasive devices, methods, and systems for modifying tissues
US20060095032A1 (en) 1999-11-16 2006-05-04 Jerome Jackson Methods and systems for determining physiologic characteristics for treatment of the esophagus
US6551310B1 (en) 1999-11-16 2003-04-22 Robert A. Ganz System and method of treating abnormal tissue in the human esophagus
US20040215235A1 (en) 1999-11-16 2004-10-28 Barrx, Inc. Methods and systems for determining physiologic characteristics for treatment of the esophagus
US20040215296A1 (en) * 1999-11-16 2004-10-28 Barrx, Inc. System and method for treating abnormal epithelium in an esophagus
ES2306706T3 (en) 2000-03-06 2008-11-16 Salient Surgical Technologies, Inc. FLUID SUPPLY SYSTEM AND CONTROLLER FOR ELECTROCHURGICAL DEVICES.
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US7811282B2 (en) 2000-03-06 2010-10-12 Salient Surgical Technologies, Inc. Fluid-assisted electrosurgical devices, electrosurgical unit with pump and methods of use thereof
US8048070B2 (en) 2000-03-06 2011-11-01 Salient Surgical Technologies, Inc. Fluid-assisted medical devices, systems and methods
US6689131B2 (en) 2001-03-08 2004-02-10 Tissuelink Medical, Inc. Electrosurgical device having a tissue reduction sensor
US7220266B2 (en) 2000-05-19 2007-05-22 C. R. Bard, Inc. Tissue capturing and suturing device and method
US7737109B2 (en) * 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
WO2002013854A1 (en) * 2000-08-11 2002-02-21 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US20020177847A1 (en) * 2001-03-30 2002-11-28 Long Gary L. Endoscopic ablation system with flexible coupling
US20030181900A1 (en) * 2002-03-25 2003-09-25 Long Gary L. Endoscopic ablation system with a plurality of electrodes
US7097644B2 (en) 2001-03-30 2006-08-29 Ethicon Endo-Surgery, Inc. Medical device with improved wall construction
US20020183739A1 (en) * 2001-03-30 2002-12-05 Long Gary L. Endoscopic ablation system with sealed sheath
AU2002315027A1 (en) * 2001-05-15 2002-11-25 Children's Medical Center Corporation Methods and apparatus for application of micro-mechanical forces to tissues
US20030013972A1 (en) 2001-05-29 2003-01-16 Makin Inder Raj. S. Treatment of lung lesions using ultrasound
US7846096B2 (en) 2001-05-29 2010-12-07 Ethicon Endo-Surgery, Inc. Method for monitoring of medical treatment using pulse-echo ultrasound
US10835307B2 (en) 2001-06-12 2020-11-17 Ethicon Llc Modular battery powered handheld surgical instrument containing elongated multi-layered shaft
US20030120328A1 (en) * 2001-12-21 2003-06-26 Transneuronix, Inc. Medical implant device for electrostimulation using discrete micro-electrodes
US7137981B2 (en) 2002-03-25 2006-11-21 Ethicon Endo-Surgery, Inc. Endoscopic ablation system with a distally mounted image sensor
US6963772B2 (en) * 2002-04-17 2005-11-08 The Board Of Trustees Of The Leland Stanford Junior University User-retainable temperature and impedance monitoring methods and devices
US6960233B1 (en) * 2002-12-10 2005-11-01 Torax Medical, Inc. Methods and apparatus for improving the function of biological passages
US7695427B2 (en) 2002-04-26 2010-04-13 Torax Medical, Inc. Methods and apparatus for treating body tissue sphincters and the like
US20040082859A1 (en) 2002-07-01 2004-04-29 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
EP1572020A4 (en) 2002-10-29 2006-05-03 Tissuelink Medical Inc Fluid-assisted electrosurgical scissors and methods
AU2003293191B2 (en) 2002-11-29 2008-08-07 William E. Cohn Apparatus and method for manipulating tissue
US7104985B2 (en) * 2003-03-06 2006-09-12 Martinelli Michael A Apparatus and method for causing selective necrosis of abnormal cells
WO2004110556A1 (en) * 2003-04-16 2004-12-23 New York University Combined transesophageal echocardiography and transesophageal cardioversion probe
US7311701B2 (en) * 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
EP1656070B1 (en) * 2003-08-11 2009-09-23 Wilson-Cook Medical Inc. Surgical implant
US20050038489A1 (en) * 2003-08-14 2005-02-17 Grill Warren M. Electrode array for use in medical stimulation and methods thereof
US7294125B2 (en) * 2003-08-22 2007-11-13 Scimed Life Systems, Inc. Methods of delivering energy to body portions to produce a therapeutic response
US7160294B2 (en) * 2003-09-02 2007-01-09 Curon Medical, Inc. Systems and methods for treating hemorrhoids
NL1024658C2 (en) * 2003-10-29 2005-05-02 Univ Medisch Centrum Utrecht Catheter and method, in particular for ablation and the like.
EP1690490B1 (en) * 2003-11-11 2012-04-18 Olympus Corporation Capsule type medical device system
US7347863B2 (en) 2004-05-07 2008-03-25 Usgi Medical, Inc. Apparatus and methods for manipulating and securing tissue
US7150745B2 (en) 2004-01-09 2006-12-19 Barrx Medical, Inc. Devices and methods for treatment of luminal tissue
AU2011221375B2 (en) * 2004-01-09 2012-10-18 Covidien Lp System and method for treating abnormal epithelium in an esophagus
US7727232B1 (en) 2004-02-04 2010-06-01 Salient Surgical Technologies, Inc. Fluid-assisted medical devices and methods
US20050203441A1 (en) * 2004-03-12 2005-09-15 Voegele James W. Electrode sleeve for biopsy device
US8257394B2 (en) 2004-05-07 2012-09-04 Usgi Medical, Inc. Apparatus and methods for positioning and securing anchors
US7883468B2 (en) 2004-05-18 2011-02-08 Ethicon Endo-Surgery, Inc. Medical system having an ultrasound source and an acoustic coupling medium
US7951095B2 (en) 2004-05-20 2011-05-31 Ethicon Endo-Surgery, Inc. Ultrasound medical system
US7473250B2 (en) * 2004-05-21 2009-01-06 Ethicon Endo-Surgery, Inc. Ultrasound medical system and method
US7806839B2 (en) 2004-06-14 2010-10-05 Ethicon Endo-Surgery, Inc. System and method for ultrasound therapy using grating lobes
US7533439B2 (en) * 2004-06-25 2009-05-19 Healthy Gain Investments Limited Handle assembly for a cleaning apparatus
US7232438B2 (en) 2004-07-09 2007-06-19 Ethicon Endo-Surgery, Inc. Ablation device with clear probe
US7244270B2 (en) * 2004-09-16 2007-07-17 Evera Medical Systems and devices for soft tissue augmentation
US20060058892A1 (en) * 2004-09-16 2006-03-16 Lesh Michael D Valved tissue augmentation implant
US7641688B2 (en) 2004-09-16 2010-01-05 Evera Medical, Inc. Tissue augmentation device
JP2008513132A (en) * 2004-09-16 2008-05-01 ジュヴァ・メディカル・インコーポレーテッド Tissue augmentation device
US20060058891A1 (en) * 2004-09-16 2006-03-16 Lesh Michael D Transformable tissue bulking device
US7949407B2 (en) 2004-11-05 2011-05-24 Asthmatx, Inc. Energy delivery devices and methods
JP4149987B2 (en) * 2004-11-09 2008-09-17 フジノン株式会社 Endoscope device
WO2006068970A2 (en) * 2004-12-21 2006-06-29 Mitchell Roslin Anastomotic outlet revision
US7407503B2 (en) * 2004-12-21 2008-08-05 Ethicon Endo-Surgey, Inc. Medical-treatment electrode assembly having treatment-monitoring application
US20060276861A1 (en) * 2005-06-01 2006-12-07 Lin J T Non-invasive method and system for the treatment of snoring and nasal obstruction
US20070016184A1 (en) * 2005-07-14 2007-01-18 Ethicon Endo-Surgery, Inc. Medical-treatment electrode assembly and method for medical treatment
US8034051B2 (en) 2005-07-15 2011-10-11 Atricure, Inc. Ablation device with sensor
ITBO20050495A1 (en) * 2005-07-22 2007-01-23 Fiab Spa EXOGUE PIPELINE
US20070050001A1 (en) * 2005-08-26 2007-03-01 Solarant Medical, Inc. Adjustable open loop control devices and methods
US20070083121A1 (en) * 2005-09-26 2007-04-12 Hastings Harold M Transesophageal ultrasound probe with reduced width
US20070083192A1 (en) * 2005-10-07 2007-04-12 Eric Welch Apparatus and method for ablation of targeted tissue
US9028406B2 (en) * 2005-10-18 2015-05-12 Pneumoflex Systems, Llc Oral-esophageal-gastric device to diagnose reflux and/or emesis
US8597184B2 (en) 2005-10-18 2013-12-03 Pneumoflex Systems, Llc Techniques for evaluating urinary stress incontinence and use of involuntary reflex cough as a medical diagnostic tool
US9011328B2 (en) * 2005-10-18 2015-04-21 Pneumoflex Systems, Llc Oral-esophageal-gastric device with esophageal cuff to reduce gastric reflux and/or emesis
US8702694B2 (en) 2005-11-23 2014-04-22 Covidien Lp Auto-aligning ablating device and method of use
JP5438323B2 (en) * 2005-11-23 2014-03-12 コヴィディエン リミテッド パートナーシップ High precision cutting device
US7959627B2 (en) 2005-11-23 2011-06-14 Barrx Medical, Inc. Precision ablating device
US7997278B2 (en) 2005-11-23 2011-08-16 Barrx Medical, Inc. Precision ablating method
US20070142699A1 (en) * 2005-12-16 2007-06-21 Acoustx Corporation Methods and implantable apparatuses for treating an esophageal disorder such as gastroesophageal reflux disease
US20070142884A1 (en) * 2005-12-16 2007-06-21 Acoustx Corporation Methods and apparatuses for treating an esophageal disorder such as gastroesophageal reflux disease
US20070239011A1 (en) 2006-01-13 2007-10-11 Mirabilis Medica, Inc. Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body
US8726909B2 (en) 2006-01-27 2014-05-20 Usgi Medical, Inc. Methods and apparatus for revision of obesity procedures
CA2649119A1 (en) 2006-04-13 2007-12-13 Mirabilis Medica, Inc. Methods and apparatus for the treatment of menometrorrhagia, endometrial pathology, and cervical neoplasia using high intensity focused ultrasound energy
US8401650B2 (en) 2008-04-10 2013-03-19 Electrocore Llc Methods and apparatus for electrical treatment using balloon and electrode
US8209034B2 (en) * 2008-12-18 2012-06-26 Electrocore Llc Methods and apparatus for electrical stimulation treatment using esophageal balloon and electrode
US20070244529A1 (en) * 2006-04-18 2007-10-18 Zoom Therapeutics, Inc. Apparatus and methods for treatment of nasal tissue
US9020597B2 (en) 2008-11-12 2015-04-28 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
EP2021846B1 (en) 2006-05-19 2017-05-03 Koninklijke Philips N.V. Ablation device with optimized input power profile
WO2007140331A2 (en) 2006-05-25 2007-12-06 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US20080027520A1 (en) * 2006-07-25 2008-01-31 Zoom Therapeutics, Inc. Laser treatment of tissue
US11577077B2 (en) 2006-10-09 2023-02-14 Endostim, Inc. Systems and methods for electrical stimulation of biological systems
US9724510B2 (en) 2006-10-09 2017-08-08 Endostim, Inc. System and methods for electrical stimulation of biological systems
US9345879B2 (en) * 2006-10-09 2016-05-24 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US20150224310A1 (en) * 2006-10-09 2015-08-13 Endostim, Inc. Device and Implantation System for Electrical Stimulation of Biological Systems
US20080140068A1 (en) * 2006-12-07 2008-06-12 Cierra, Inc. Multi-electrode apparatus for tissue welding and ablation
US7655004B2 (en) 2007-02-15 2010-02-02 Ethicon Endo-Surgery, Inc. Electroporation ablation apparatus, system, and method
US8092472B2 (en) * 2007-02-22 2012-01-10 Cerier Jeffrey C Methods and devices for endoscopic treatment of organs
JP2008259701A (en) * 2007-04-12 2008-10-30 Olympus Corp Apparatus inserted into living body
JP2010525873A (en) * 2007-05-01 2010-07-29 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド Wound healing device
WO2008137757A1 (en) 2007-05-04 2008-11-13 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation for treatment of obesity
US8784338B2 (en) 2007-06-22 2014-07-22 Covidien Lp Electrical means to normalize ablational energy transmission to a luminal tissue surface of varying size
KR101547931B1 (en) 2007-07-06 2015-08-28 코비디엔 엘피 Ablation in the gastrointestinal tract to achieve hemostasis and eradicate lesions with a propensity for bleeding
WO2009009443A1 (en) 2007-07-06 2009-01-15 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation
US8646460B2 (en) 2007-07-30 2014-02-11 Covidien Lp Cleaning device and methods
US8273012B2 (en) 2007-07-30 2012-09-25 Tyco Healthcare Group, Lp Cleaning device and methods
US8052604B2 (en) 2007-07-31 2011-11-08 Mirabilis Medica Inc. Methods and apparatus for engagement and coupling of an intracavitory imaging and high intensity focused ultrasound probe
WO2009025824A1 (en) 2007-08-20 2009-02-26 Medtronic, Inc. Implantable medical lead with biased electrode
EP2190528B1 (en) * 2007-08-20 2014-10-08 Medtronic, Inc. Evaluating therapeutic stimulation electrode configurations based on physiological responses
US8579897B2 (en) 2007-11-21 2013-11-12 Ethicon Endo-Surgery, Inc. Bipolar forceps
WO2009042268A1 (en) * 2007-09-28 2009-04-02 Choi George Y Device and methods for treatment of tissue
US20090112059A1 (en) 2007-10-31 2009-04-30 Nobis Rudolph H Apparatus and methods for closing a gastrotomy
US8187270B2 (en) 2007-11-07 2012-05-29 Mirabilis Medica Inc. Hemostatic spark erosion tissue tunnel generator with integral treatment providing variable volumetric necrotization of tissue
US8439907B2 (en) 2007-11-07 2013-05-14 Mirabilis Medica Inc. Hemostatic tissue tunnel generator for inserting treatment apparatus into tissue of a patient
HUE054386T2 (en) * 2008-01-29 2021-09-28 Implantica Patent Ltd Apparatus for treating obesity
US20090198331A1 (en) * 2008-02-01 2009-08-06 Kesten Randy J Implantable prosthesis with open cell flow regulation
US20090198329A1 (en) 2008-02-01 2009-08-06 Kesten Randy J Breast implant with internal flow dampening
US8971997B2 (en) * 2008-03-24 2015-03-03 The Regents Of The University Of Michigan Non-contact infrared fiber-optic device for measuring temperature in a vessel
US8682449B2 (en) 2008-04-10 2014-03-25 ElectroCore, LLC Methods and apparatus for transcranial stimulation
US8771260B2 (en) 2008-05-30 2014-07-08 Ethicon Endo-Surgery, Inc. Actuating and articulating surgical device
US8906035B2 (en) 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
US8403926B2 (en) 2008-06-05 2013-03-26 Ethicon Endo-Surgery, Inc. Manually articulating devices
US8888792B2 (en) 2008-07-14 2014-11-18 Ethicon Endo-Surgery, Inc. Tissue apposition clip application devices and methods
US8216161B2 (en) 2008-08-06 2012-07-10 Mirabilis Medica Inc. Optimization and feedback control of HIFU power deposition through the frequency analysis of backscattered HIFU signals
US9089360B2 (en) 2008-08-06 2015-07-28 Ethicon Endo-Surgery, Inc. Devices and techniques for cutting and coagulating tissue
US9248318B2 (en) 2008-08-06 2016-02-02 Mirabilis Medica Inc. Optimization and feedback control of HIFU power deposition through the analysis of detected signal characteristics
US9050449B2 (en) 2008-10-03 2015-06-09 Mirabilis Medica, Inc. System for treating a volume of tissue with high intensity focused ultrasound
CA2739425A1 (en) 2008-10-03 2010-04-08 Mirabilis Medica, Inc. Method and apparatus for treating tissues with hifu
US9561068B2 (en) * 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US20100094270A1 (en) 2008-10-06 2010-04-15 Sharma Virender K Method and Apparatus for Tissue Ablation
US10695126B2 (en) 2008-10-06 2020-06-30 Santa Anna Tech Llc Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue
US10064697B2 (en) * 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US8157834B2 (en) 2008-11-25 2012-04-17 Ethicon Endo-Surgery, Inc. Rotational coupling device for surgical instrument with flexible actuators
WO2010080886A1 (en) 2009-01-09 2010-07-15 Recor Medical, Inc. Methods and apparatus for treatment of mitral valve in insufficiency
US8361066B2 (en) 2009-01-12 2013-01-29 Ethicon Endo-Surgery, Inc. Electrical ablation devices
JP5674680B2 (en) * 2009-01-15 2015-02-25 コーニンクレッカ フィリップス エヌ ヴェ Electrophysiology catheter
US8747297B2 (en) * 2009-03-02 2014-06-10 Olympus Corporation Endoscopic heart surgery method
JP5415925B2 (en) * 2009-03-02 2014-02-12 オリンパス株式会社 Endoscope
US8663220B2 (en) 2009-07-15 2014-03-04 Ethicon Endo-Surgery, Inc. Ultrasonic surgical instruments
US9474565B2 (en) 2009-09-22 2016-10-25 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
WO2011037068A1 (en) * 2009-09-22 2011-03-31 オリンパス株式会社 Space-securing device
US10386990B2 (en) 2009-09-22 2019-08-20 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US9775664B2 (en) 2009-09-22 2017-10-03 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9750563B2 (en) 2009-09-22 2017-09-05 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
AU2015200049B2 (en) * 2009-10-02 2016-11-10 Medtronic Xomed, Inc. Endotracheal tube apparatus
CN102781510B (en) 2009-10-02 2015-03-25 麦德托尼克艾克斯欧麦德股份有限公司 Endotracheal tube apparatus
US11090104B2 (en) 2009-10-09 2021-08-17 Cilag Gmbh International Surgical generator for ultrasonic and electrosurgical devices
AU2010308498B2 (en) 2009-10-21 2016-02-11 Apollo Endosurgery, Inc. Bariatric device and method for weight loss
US20110098694A1 (en) * 2009-10-28 2011-04-28 Ethicon Endo-Surgery, Inc. Methods and instruments for treating cardiac tissue through a natural orifice
US20110098704A1 (en) 2009-10-28 2011-04-28 Ethicon Endo-Surgery, Inc. Electrical ablation devices
US8608652B2 (en) 2009-11-05 2013-12-17 Ethicon Endo-Surgery, Inc. Vaginal entry surgical devices, kit, system, and method
US20120232361A1 (en) * 2009-11-20 2012-09-13 Allergan, Inc. Bariatric instrument or accessory with sensors
US8496574B2 (en) 2009-12-17 2013-07-30 Ethicon Endo-Surgery, Inc. Selectively positionable camera for surgical guide tube assembly
US8506564B2 (en) 2009-12-18 2013-08-13 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
US9028483B2 (en) 2009-12-18 2015-05-12 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
US9005198B2 (en) 2010-01-29 2015-04-14 Ethicon Endo-Surgery, Inc. Surgical instrument comprising an electrode
US8469981B2 (en) 2010-02-11 2013-06-25 Ethicon Endo-Surgery, Inc. Rotatable cutting implement arrangements for ultrasonic surgical instruments
US8447404B2 (en) 2010-03-05 2013-05-21 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US11717681B2 (en) 2010-03-05 2023-08-08 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
ES2536055T3 (en) 2010-03-15 2015-05-20 Apollo Endosurgery, Inc. Bariatric device and weight loss method
EP2595558A2 (en) * 2010-07-23 2013-05-29 Board of Regents of the University of Texas System Surgical cooling device
US20120078141A1 (en) * 2010-09-03 2012-03-29 Knowlton Edward W Systems and methods for using reverse thermal gradient to non-invasively heat a subjacent soft tissue structure
JP2013543423A (en) 2010-10-18 2013-12-05 カーディオソニック リミテッド Tissue treatment
ES2565348T3 (en) 2010-10-18 2016-04-04 Apollo Endosurgery, Inc. Intragastric implant reagent devices
US8870966B2 (en) 2010-10-18 2014-10-28 Apollo Endosurgery, Inc. Intragastric balloon for treating obesity
WO2012054514A2 (en) 2010-10-18 2012-04-26 Allergan, Inc. Intragastric implants with duodenal anchors
US9463107B2 (en) 2010-10-18 2016-10-11 Apollo Endosurgery, Inc. Variable size intragastric implant devices
US9566456B2 (en) 2010-10-18 2017-02-14 CardioSonic Ltd. Ultrasound transceiver and cooling thereof
US9028417B2 (en) 2010-10-18 2015-05-12 CardioSonic Ltd. Ultrasound emission element
US9233016B2 (en) 2010-10-18 2016-01-12 Apollo Endosurgery, Inc. Elevating stomach stimulation device
US8696581B2 (en) 2010-10-18 2014-04-15 CardioSonic Ltd. Ultrasound transducer and uses thereof
US9398969B2 (en) 2010-10-19 2016-07-26 Apollo Endosurgery, Inc. Upper stomach gastric implants
US9198790B2 (en) 2010-10-19 2015-12-01 Apollo Endosurgery, Inc. Upper stomach gastric implants
US8864840B2 (en) 2010-10-19 2014-10-21 Apollo Endosurgery, Inc. Intragastric implants with collapsible frames
US9498365B2 (en) 2010-10-19 2016-11-22 Apollo Endosurgery, Inc. Intragastric implants with multiple fluid chambers
ES2593753T3 (en) 2010-10-19 2016-12-13 Apollo Endosurgery, Inc. Duodenal sleeve with anchor without perforation
US8920447B2 (en) 2010-10-19 2014-12-30 Apollo Endosurgery, Inc. Articulated gastric implant clip
US9095405B2 (en) 2010-10-19 2015-08-04 Apollo Endosurgery, Inc. Space-filling intragastric implants with fluid flow
US20120109118A1 (en) * 2010-10-29 2012-05-03 Medtronic Ablation Frontiers Llc Cryogenic-radiofrequency ablation system
CN103442631A (en) 2010-11-27 2013-12-11 Securus医药集团股份有限公司 Ablation and temperature measurement devices
US20120165842A1 (en) * 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Endoluminal fold creation
US20120190938A1 (en) * 2011-01-20 2012-07-26 Pneumoflex Systems, Llc System and method of diagnosing acid reflux using involuntary reflex cough test
US10092291B2 (en) 2011-01-25 2018-10-09 Ethicon Endo-Surgery, Inc. Surgical instrument with selectively rigidizable features
US9233241B2 (en) 2011-02-28 2016-01-12 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9254169B2 (en) 2011-02-28 2016-02-09 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
US9314620B2 (en) 2011-02-28 2016-04-19 Ethicon Endo-Surgery, Inc. Electrical ablation devices and methods
WO2012125785A1 (en) 2011-03-17 2012-09-20 Ethicon Endo-Surgery, Inc. Hand held surgical device for manipulating an internal magnet assembly within a patient
US10278774B2 (en) 2011-03-18 2019-05-07 Covidien Lp Selectively expandable operative element support structure and methods of use
AU2012242533B2 (en) 2011-04-14 2016-10-20 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
WO2013022077A1 (en) * 2011-08-10 2013-02-14 国立大学法人 滋賀医科大学 Microwave surgical instrument
EP2744437B1 (en) 2011-08-19 2020-12-09 Cook Medical Technologies LLC Ablation cap
AU2012298709B2 (en) 2011-08-25 2015-04-16 Covidien Lp Systems, devices, and methods for treatment of luminal tissue
US9925367B2 (en) 2011-09-02 2018-03-27 Endostim, Inc. Laparoscopic lead implantation method
US9113879B2 (en) 2011-12-15 2015-08-25 Ethicon Endo-Surgery, Inc. Devices and methods for endoluminal plication
US9931079B2 (en) 2012-01-04 2018-04-03 Medtronic Xomed, Inc. Clamp for securing a terminal end of a wire to a surface electrode
WO2013134780A1 (en) * 2012-03-09 2013-09-12 Petersohn M D Jeffrey Device for therapeutic delivery of radio frequency energy
US8992547B2 (en) 2012-03-21 2015-03-31 Ethicon Endo-Surgery, Inc. Methods and devices for creating tissue plications
JP2012130791A (en) * 2012-04-09 2012-07-12 Olympus Corp Instrument inserted into living body
US9439668B2 (en) 2012-04-09 2016-09-13 Ethicon Endo-Surgery, Llc Switch arrangements for ultrasonic surgical instruments
US10357304B2 (en) 2012-04-18 2019-07-23 CardioSonic Ltd. Tissue treatment
US9186053B2 (en) 2012-05-03 2015-11-17 Covidien Lp Methods of using light to repair hernia defects
US9427255B2 (en) 2012-05-14 2016-08-30 Ethicon Endo-Surgery, Inc. Apparatus for introducing a steerable camera assembly into a patient
US11357447B2 (en) 2012-05-31 2022-06-14 Sonivie Ltd. Method and/or apparatus for measuring renal denervation effectiveness
US20140005705A1 (en) 2012-06-29 2014-01-02 Ethicon Endo-Surgery, Inc. Surgical instruments with articulating shafts
US9351754B2 (en) 2012-06-29 2016-05-31 Ethicon Endo-Surgery, Llc Ultrasonic surgical instruments with distally positioned jaw assemblies
US9326788B2 (en) 2012-06-29 2016-05-03 Ethicon Endo-Surgery, Llc Lockout mechanism for use with robotic electrosurgical device
US9198714B2 (en) 2012-06-29 2015-12-01 Ethicon Endo-Surgery, Inc. Haptic feedback devices for surgical robot
US9408622B2 (en) 2012-06-29 2016-08-09 Ethicon Endo-Surgery, Llc Surgical instruments with articulating shafts
US9393037B2 (en) 2012-06-29 2016-07-19 Ethicon Endo-Surgery, Llc Surgical instruments with articulating shafts
US9226767B2 (en) 2012-06-29 2016-01-05 Ethicon Endo-Surgery, Inc. Closed feedback control for electrosurgical device
US9078662B2 (en) 2012-07-03 2015-07-14 Ethicon Endo-Surgery, Inc. Endoscopic cap electrode and method for using the same
US20140018888A1 (en) * 2012-07-16 2014-01-16 Boston Scientific Scimed, Inc. Flow controlled radiofrequency medical balloon
US9545290B2 (en) 2012-07-30 2017-01-17 Ethicon Endo-Surgery, Inc. Needle probe guide
US9572623B2 (en) 2012-08-02 2017-02-21 Ethicon Endo-Surgery, Inc. Reusable electrode and disposable sheath
US10314649B2 (en) 2012-08-02 2019-06-11 Ethicon Endo-Surgery, Inc. Flexible expandable electrode and method of intraluminal delivery of pulsed power
US9277957B2 (en) 2012-08-15 2016-03-08 Ethicon Endo-Surgery, Inc. Electrosurgical devices and methods
AU2013305543A1 (en) 2012-08-23 2015-03-19 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US20150080867A1 (en) * 2012-09-19 2015-03-19 Wolfgang Neuberger Gastric Reflux Treatment with Lasers
US9526570B2 (en) 2012-10-04 2016-12-27 Cook Medical Technologies Llc Tissue cutting cap
US9095367B2 (en) 2012-10-22 2015-08-04 Ethicon Endo-Surgery, Inc. Flexible harmonic waveguides/blades for surgical instruments
US20140135804A1 (en) 2012-11-15 2014-05-15 Ethicon Endo-Surgery, Inc. Ultrasonic and electrosurgical devices
US9060744B2 (en) 2012-11-29 2015-06-23 Medtronic Xomed, Inc. Endobronchial tube apparatus
US9364277B2 (en) 2012-12-13 2016-06-14 Cook Medical Technologies Llc RF energy controller and method for electrosurgical medical devices
US9204921B2 (en) 2012-12-13 2015-12-08 Cook Medical Technologies Llc RF energy controller and method for electrosurgical medical devices
EP2945556A4 (en) * 2013-01-17 2016-08-31 Virender K Sharma Method and apparatus for tissue ablation
US9498619B2 (en) 2013-02-26 2016-11-22 Endostim, Inc. Implantable electrical stimulation leads
US10098527B2 (en) 2013-02-27 2018-10-16 Ethidcon Endo-Surgery, Inc. System for performing a minimally invasive surgical procedure
US9913594B2 (en) 2013-03-14 2018-03-13 Medtronic Xomed, Inc. Compliant electrode for EMG endotracheal tube
WO2014188430A2 (en) 2013-05-23 2014-11-27 CardioSonic Ltd. Devices and methods for renal denervation and assessment thereof
US9919119B2 (en) 2013-07-31 2018-03-20 Shannon Sovndal Gum elastic bougie introducer with tactile depth and orientation indicator
WO2015034867A2 (en) 2013-09-03 2015-03-12 Endostim, Inc. Methods and systems of electrode polarity switching in electrical stimulation therapy
US9814514B2 (en) * 2013-09-13 2017-11-14 Ethicon Llc Electrosurgical (RF) medical instruments for cutting and coagulating tissue
GB2521228A (en) 2013-12-16 2015-06-17 Ethicon Endo Surgery Inc Medical device
US9795436B2 (en) 2014-01-07 2017-10-24 Ethicon Llc Harvesting energy from a surgical generator
US9554854B2 (en) 2014-03-18 2017-01-31 Ethicon Endo-Surgery, Llc Detecting short circuits in electrosurgical medical devices
US10092310B2 (en) 2014-03-27 2018-10-09 Ethicon Llc Electrosurgical devices
US9737355B2 (en) 2014-03-31 2017-08-22 Ethicon Llc Controlling impedance rise in electrosurgical medical devices
US9913680B2 (en) 2014-04-15 2018-03-13 Ethicon Llc Software algorithms for electrosurgical instruments
US10285724B2 (en) 2014-07-31 2019-05-14 Ethicon Llc Actuation mechanisms and load adjustment assemblies for surgical instruments
WO2016081468A2 (en) 2014-11-17 2016-05-26 Endostim, Inc. Implantable electro-medical device programmable for improved operational life
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10245095B2 (en) 2015-02-06 2019-04-02 Ethicon Llc Electrosurgical instrument with rotation and articulation mechanisms
US10898256B2 (en) 2015-06-30 2021-01-26 Ethicon Llc Surgical system with user adaptable techniques based on tissue impedance
US11051873B2 (en) 2015-06-30 2021-07-06 Cilag Gmbh International Surgical system with user adaptable techniques employing multiple energy modalities based on tissue parameters
US10034704B2 (en) 2015-06-30 2018-07-31 Ethicon Llc Surgical instrument with user adaptable algorithms
US11129669B2 (en) 2015-06-30 2021-09-28 Cilag Gmbh International Surgical system with user adaptable techniques based on tissue type
US10765470B2 (en) 2015-06-30 2020-09-08 Ethicon Llc Surgical system with user adaptable techniques employing simultaneous energy modalities based on tissue parameters
US10631966B2 (en) 2015-08-12 2020-04-28 Innoventions Ltd System for sphincteric and other tissue regeneration
US11058475B2 (en) 2015-09-30 2021-07-13 Cilag Gmbh International Method and apparatus for selecting operations of a surgical instrument based on user intention
US10595930B2 (en) 2015-10-16 2020-03-24 Ethicon Llc Electrode wiping surgical device
US10719236B2 (en) * 2015-11-20 2020-07-21 Arm Ltd. Memory controller with non-volatile buffer for persistent memory operations
US10709469B2 (en) 2016-01-15 2020-07-14 Ethicon Llc Modular battery powered handheld surgical instrument with energy conservation techniques
US11229471B2 (en) 2016-01-15 2022-01-25 Cilag Gmbh International Modular battery powered handheld surgical instrument with selective application of energy based on tissue characterization
US11129670B2 (en) 2016-01-15 2021-09-28 Cilag Gmbh International Modular battery powered handheld surgical instrument with selective application of energy based on button displacement, intensity, or local tissue characterization
US10555769B2 (en) 2016-02-22 2020-02-11 Ethicon Llc Flexible circuits for electrosurgical instrument
US10456193B2 (en) 2016-05-03 2019-10-29 Ethicon Llc Medical device with a bilateral jaw configuration for nerve stimulation
US11331140B2 (en) 2016-05-19 2022-05-17 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
US10376305B2 (en) 2016-08-05 2019-08-13 Ethicon Llc Methods and systems for advanced harmonic energy
WO2018094207A1 (en) 2016-11-17 2018-05-24 Endostim, Inc. Modular stimulation system for the treatment of gastrointestinal disorders
US11266430B2 (en) 2016-11-29 2022-03-08 Cilag Gmbh International End effector control and calibration
WO2018173053A1 (en) 2017-03-20 2018-09-27 Sonievie Ltd. Pulmonary hypertension treatment method and/or system
US11110240B2 (en) 2017-09-07 2021-09-07 Medtronic Xomed, Inc. Endotracheal tube with tube coating
US11291499B2 (en) * 2017-12-26 2022-04-05 Inmode Ltd. Device and method for treatment of sleep disorders
WO2019232432A1 (en) 2018-06-01 2019-12-05 Santa Anna Tech Llc Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems
US11759251B2 (en) 2019-12-30 2023-09-19 Cilag Gmbh International Control program adaptation based on device status and user input
US11812957B2 (en) 2019-12-30 2023-11-14 Cilag Gmbh International Surgical instrument comprising a signal interference resolution system
US20210196359A1 (en) 2019-12-30 2021-07-01 Ethicon Llc Electrosurgical instruments with electrodes having energy focusing features
US11660089B2 (en) 2019-12-30 2023-05-30 Cilag Gmbh International Surgical instrument comprising a sensing system
US11911063B2 (en) 2019-12-30 2024-02-27 Cilag Gmbh International Techniques for detecting ultrasonic blade to electrode contact and reducing power to ultrasonic blade
US11779329B2 (en) 2019-12-30 2023-10-10 Cilag Gmbh International Surgical instrument comprising a flex circuit including a sensor system
US11779387B2 (en) 2019-12-30 2023-10-10 Cilag Gmbh International Clamp arm jaw to minimize tissue sticking and improve tissue control
US11707318B2 (en) 2019-12-30 2023-07-25 Cilag Gmbh International Surgical instrument with jaw alignment features
US11696776B2 (en) 2019-12-30 2023-07-11 Cilag Gmbh International Articulatable surgical instrument
US11786291B2 (en) 2019-12-30 2023-10-17 Cilag Gmbh International Deflectable support of RF energy electrode with respect to opposing ultrasonic blade
US11452525B2 (en) 2019-12-30 2022-09-27 Cilag Gmbh International Surgical instrument comprising an adjustment system
US20210196358A1 (en) 2019-12-30 2021-07-01 Ethicon Llc Electrosurgical instrument with electrodes biasing support
WO2023052943A1 (en) * 2021-09-29 2023-04-06 Cilag Gmbh International Surgical devices, systems, and methods for control of one visualization with another
WO2023052945A1 (en) * 2021-09-29 2023-04-06 Cilag Gmbh International Surgical devices, systems, and methods for control of one visualization with another
WO2023052941A1 (en) * 2021-09-29 2023-04-06 Cilag Gmbh International Surgical system for delivering energy to tissue in an anatomic space and monitoring a tissue parameter in a different anatomic space

Citations (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4295464A (en) * 1980-03-21 1981-10-20 Shihata Alfred A Ureteric stone extractor with two ballooned catheters
US4396019A (en) * 1978-03-06 1983-08-02 Perry Jr John D Vaginal myograph method and apparatus
US4706688A (en) * 1981-05-18 1987-11-17 Don Michael T Anthony Non-invasive cardiac device
US4765331A (en) * 1987-02-10 1988-08-23 Circon Corporation Electrosurgical device with treatment arc of less than 360 degrees
US5026366A (en) * 1984-03-01 1991-06-25 Cardiovascular Laser Systems, Inc. Angioplasty catheter and method of use thereof
US5056532A (en) * 1989-07-25 1991-10-15 Medtronic, Inc. Esophageal pacing lead
US5103804A (en) * 1990-07-03 1992-04-14 Boston Scientific Corporation Expandable tip hemostatic probes and the like
US5249585A (en) * 1988-07-28 1993-10-05 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
US5341807A (en) * 1992-06-30 1994-08-30 American Cardiac Ablation Co., Inc. Ablation catheter positioning system
US5370679A (en) * 1992-10-13 1994-12-06 Atlee, Iii; John L. Esophageal probe for transesophageal cardiac stimulation
US5395363A (en) * 1993-06-29 1995-03-07 Utah Medical Products Diathermy coagulation and ablation apparatus and method
US5397321A (en) * 1993-07-30 1995-03-14 Ep Technologies, Inc. Variable curve electrophysiology catheter
US5409458A (en) * 1993-11-10 1995-04-25 Medtronic, Inc. Grooved balloon for dilatation catheter
US5413557A (en) * 1993-08-24 1995-05-09 Pameda N.V. Dilatation catheter with eccentric balloon
US5425364A (en) * 1991-02-15 1995-06-20 Cardiac Pathways Corporation Flexible strip assembly without feedthrough holes and device utilizing the same
US5443470A (en) * 1992-05-01 1995-08-22 Vesta Medical, Inc. Method and apparatus for endometrial ablation
US5454782A (en) * 1994-08-11 1995-10-03 Perkins; Rodney C. Translumenal circumferential energy delivery device
US5540655A (en) * 1992-08-12 1996-07-30 Vidamed, Inc. PBH ablation method and apparatus
US5575787A (en) * 1993-09-20 1996-11-19 Abela Laser Systems, Inc. Cardiac ablation catheters and method
US5575788A (en) * 1994-06-24 1996-11-19 Stuart D. Edwards Thin layer ablation apparatus
US5651785A (en) * 1993-09-20 1997-07-29 Abela Laser Systems, Inc. Optical fiber catheter and method
US5658278A (en) * 1992-12-01 1997-08-19 Cardiac Pathways, Inc. Catheter for RF ablation with cooled electrode and method
US5657755A (en) * 1993-03-11 1997-08-19 Desai; Jawahar M. Apparatus and method for cardiac ablation
US5681280A (en) * 1995-05-02 1997-10-28 Heart Rhythm Technologies, Inc. Catheter control system
US5688267A (en) * 1995-05-01 1997-11-18 Ep Technologies, Inc. Systems and methods for sensing multiple temperature conditions during tissue ablation
US5716340A (en) * 1991-08-02 1998-02-10 Scimed Life Systems, Inc. Blood perfusion catheter
US5718666A (en) * 1996-02-29 1998-02-17 Bioenterics Corporation Transilluminating bougie
US5776176A (en) * 1996-06-17 1998-07-07 Urologix Inc. Microwave antenna for arterial for arterial microwave applicator
US5785705A (en) * 1994-10-11 1998-07-28 Oratec Interventions, Inc. RF method for controlled depth ablation of soft tissue
US5800429A (en) * 1994-06-24 1998-09-01 Somnus Medical Technologies, Inc. Noninvasive apparatus for ablating turbinates
US5800486A (en) * 1996-06-17 1998-09-01 Urologix, Inc. Device for transurethral thermal therapy with cooling balloon
US5891134A (en) * 1996-09-24 1999-04-06 Goble; Colin System and method for applying thermal energy to tissue
US5891027A (en) * 1996-10-21 1999-04-06 Irvine Biomedical, Inc. Cardiovascular catheter system with an inflatable soft tip
US5897553A (en) * 1995-11-02 1999-04-27 Medtronic, Inc. Ball point fluid-assisted electrocautery device
US5947964A (en) * 1995-03-03 1999-09-07 Neothermia Corporation Methods and apparatus for therapeutic cauterization of predetermined volumes of biological tissue
US5957920A (en) * 1997-08-28 1999-09-28 Isothermix, Inc. Medical instruments and techniques for treatment of urinary incontinence
US5967977A (en) * 1997-10-03 1999-10-19 Medtronic, Inc. Transesophageal medical lead
US6006755A (en) * 1994-06-24 1999-12-28 Edwards; Stuart D. Method to detect and treat aberrant myoelectric activity
US6009877A (en) * 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US6015407A (en) * 1996-03-06 2000-01-18 Cardiac Pathways Corporation Combination linear ablation and cooled tip RF catheters
US6033397A (en) * 1996-03-05 2000-03-07 Vnus Medical Technologies, Inc. Method and apparatus for treating esophageal varices
US6036687A (en) * 1996-03-05 2000-03-14 Vnus Medical Technologies, Inc. Method and apparatus for treating venous insufficiency
US6044846A (en) * 1994-06-24 2000-04-04 Edwards; Stuart D. Method to treat esophageal sphincters
US6056744A (en) * 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US6066755A (en) * 1995-12-20 2000-05-23 Huels Aktiengesellschaft Amphiphilic compounds with a plurality of hydrophilic and hydrophobic groups based on carbonic acid derivatives
US6066139A (en) * 1996-05-14 2000-05-23 Sherwood Services Ag Apparatus and method for sterilization and embolization
US6073052A (en) * 1996-11-15 2000-06-06 Zelickson; Brian D. Device and method for treatment of gastroesophageal reflux disease
US6091995A (en) * 1996-11-08 2000-07-18 Surx, Inc. Devices, methods, and systems for shrinking tissues
US6092528A (en) * 1994-06-24 2000-07-25 Edwards; Stuart D. Method to treat esophageal sphincters
US6363937B1 (en) * 1995-06-07 2002-04-02 Arthrocare Corporation System and methods for electrosurgical treatment of the digestive system
US6401719B1 (en) * 1997-09-11 2002-06-11 Vnus Medical Technologies, Inc. Method of ligating hollow anatomical structures
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US6411852B1 (en) * 1997-04-07 2002-06-25 Broncus Technologies, Inc. Modification of airways by application of energy
US6464697B1 (en) * 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US20020151871A1 (en) * 2001-03-26 2002-10-17 Curon Medical, Inc. Systems and methods employing a guidewire for positioning and stabilizing external instruments deployed within the body
US20020162555A1 (en) * 2001-03-26 2002-11-07 Curon Medical, Inc. Systems and methods employing a bite block insert for positioning and stabilizing external instruments deployed within the body
US6544226B1 (en) * 2000-03-13 2003-04-08 Curon Medical, Inc. Operative devices that can be removably fitted on catheter bodies to treat tissue regions in the body
US6547776B1 (en) * 2000-01-03 2003-04-15 Curon Medical, Inc. Systems and methods for treating tissue in the crura
US6589238B2 (en) * 1998-01-14 2003-07-08 Curon Medical, Inc. Sphincter treatment device
US6645201B1 (en) * 1998-02-19 2003-11-11 Curon Medical, Inc. Systems and methods for treating dysfunctions in the intestines and rectum
US6689129B2 (en) * 1998-02-27 2004-02-10 James A Baker RF electrode array for low-rate collagen shrinkage in capsular shift procedures and methods of use
US6699243B2 (en) * 2001-09-19 2004-03-02 Curon Medical, Inc. Devices, systems and methods for treating tissue regions of the body
US6733495B1 (en) * 1999-09-08 2004-05-11 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices
US20040089313A1 (en) * 1998-02-19 2004-05-13 Curon Medical, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
US6740082B2 (en) * 1998-12-29 2004-05-25 John H. Shadduck Surgical instruments for treating gastro-esophageal reflux
US6783523B2 (en) * 1999-05-04 2004-08-31 Curon Medical, Inc. Unified systems and methods for controlling use and operation of a family of different treatment devices
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) * 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US6827713B2 (en) * 1998-02-19 2004-12-07 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552832A (en) * 1896-01-07 Instrument for treatment of strictures by electrolysis
US3734094A (en) * 1971-06-21 1973-05-22 T Calinog Multipurpose esophageal instrument
US3924628A (en) * 1972-12-01 1975-12-09 William Droegemueller Cyrogenic bladder for necrosing tissue cells
US4090518A (en) * 1975-08-25 1978-05-23 Elam James O Esophago-pharyngeal airway
US4198963A (en) * 1978-10-19 1980-04-22 Michigan Instruments, Inc. Cardiopulmonary resuscitator, defibrillator and monitor
US4311154A (en) * 1979-03-23 1982-01-19 Rca Corporation Nonsymmetrical bulb applicator for hyperthermic treatment of the body
JPS5957650A (en) * 1982-09-27 1984-04-03 呉羽化学工業株式会社 Probe for heating body cavity
JPH0644105B2 (en) * 1985-01-14 1994-06-08 オリンパス光学工業株式会社 Endoscope
US4836214A (en) * 1986-12-01 1989-06-06 Bomed Medical Manufacturing, Ltd. Esophageal electrode array for electrical bioimpedance measurement
CH675886A5 (en) * 1988-11-23 1990-11-15 Rieter Ag Maschf
US5151085A (en) * 1989-04-28 1992-09-29 Olympus Optical Co., Ltd. Apparatus for generating ultrasonic oscillation
US5387232A (en) * 1990-05-31 1995-02-07 Synchrotech Medical Corporation Method and apparatus for esophageal pacing
US5179952A (en) * 1990-08-13 1993-01-19 Arzco Medical Electronics Inc. Electrocardial stimulator probe
US5197491A (en) * 1990-09-28 1993-03-30 Brunswick Biomedical Technologies, Inc. Esophageal-stomach displacement electrode
US5720293A (en) * 1991-01-29 1998-02-24 Baxter International Inc. Diagnostic catheter with memory
US5345936A (en) 1991-02-15 1994-09-13 Cardiac Pathways Corporation Apparatus with basket assembly for endocardial mapping
FI93607C (en) * 1991-05-24 1995-05-10 John Koivukangas Cutting Remedy
US5383874A (en) * 1991-11-08 1995-01-24 Ep Technologies, Inc. Systems for identifying catheters and monitoring their use
US6053172A (en) * 1995-06-07 2000-04-25 Arthrocare Corporation Systems and methods for electrosurgical sinus surgery
US5413588A (en) * 1992-03-06 1995-05-09 Urologix, Inc. Device and method for asymmetrical thermal therapy with helical dipole microwave antenna
WO1994007446A1 (en) * 1992-10-05 1994-04-14 Boston Scientific Corporation Device and method for heating tissue
US5582609A (en) * 1993-10-14 1996-12-10 Ep Technologies, Inc. Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
WO1995010320A1 (en) * 1993-10-15 1995-04-20 Ep Technologies, Inc. Device for lengthening cardiac conduction pathways
US6071280A (en) * 1993-11-08 2000-06-06 Rita Medical Systems, Inc. Multiple electrode ablation apparatus
US6266549B1 (en) * 1993-12-06 2001-07-24 Heska Corporation Apparatus and method for evaluating cardiac functions
US5617854A (en) * 1994-06-22 1997-04-08 Munsif; Anand Shaped catheter device and method
US6464689B1 (en) * 1999-09-08 2002-10-15 Curon Medical, Inc. Graphical user interface for monitoring and controlling use of medical devices
US6023638A (en) * 1995-07-28 2000-02-08 Scimed Life Systems, Inc. System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US5904711A (en) * 1996-02-08 1999-05-18 Heartport, Inc. Expandable thoracoscopic defibrillation catheter system and method
US5800428A (en) * 1996-05-16 1998-09-01 Angeion Corporation Linear catheter ablation system
DE19626408A1 (en) * 1996-07-01 1998-01-08 Berchtold Gmbh & Co Geb Trocar for laparoscopic operations
US6039701A (en) * 1996-09-05 2000-03-21 Ob Inovations, Inc. Method and apparatus for monitoring cervical diameter
US6338726B1 (en) * 1997-02-06 2002-01-15 Vidacare, Inc. Treating urinary and other body strictures
US6024740A (en) * 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US6514249B1 (en) * 1997-07-08 2003-02-04 Atrionix, Inc. Positioning system and method for orienting an ablation element within a pulmonary vein ostium
US6179832B1 (en) * 1997-09-11 2001-01-30 Vnus Medical Technologies, Inc. Expandable catheter having two sets of electrodes
US6063082A (en) 1997-11-04 2000-05-16 Scimed Life Systems, Inc. Percutaneous myocardial revascularization basket delivery system and radiofrequency therapeutic device
US6402744B2 (en) * 1998-02-19 2002-06-11 Curon Medical, Inc. Systems and methods for forming composite lesions to treat dysfunction in sphincters and adjoining tissue regions
US7329254B2 (en) * 1998-02-19 2008-02-12 Curon Medical, Inc. Systems and methods for treating dysfunctions in the intestines and rectum that adapt to the anatomic form and structure of different individuals
US7165551B2 (en) * 1998-02-19 2007-01-23 Curon Medical, Inc. Apparatus to detect and treat aberrant myoelectric activity
US20030135206A1 (en) * 1998-02-27 2003-07-17 Curon Medical, Inc. Method for treating a sphincter
CA2320110A1 (en) 1998-02-27 1999-09-02 Curon Medical, Inc. Apparatus to electrosurgically treat esophageal sphincters
JP2002505138A (en) * 1998-03-06 2002-02-19 キューロン メディカル,インコーポレイテッド Instrument for electrosurgically treating the esophageal sphincter
US6066096A (en) * 1998-05-08 2000-05-23 Duke University Imaging probes and catheters for volumetric intraluminal ultrasound imaging and related systems
US6837885B2 (en) * 1998-05-22 2005-01-04 Scimed Life Systems, Inc. Surgical probe for supporting inflatable therapeutic devices in contact with tissue in or around body orifices and within tumors
US6245065B1 (en) * 1998-09-10 2001-06-12 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
US6238335B1 (en) * 1998-12-11 2001-05-29 Enteric Medical Technologies, Inc. Method for treating gastroesophageal reflux disease and apparatus for use therewith
US6251064B1 (en) * 1998-12-11 2001-06-26 Enteric Medical Technologies, Inc. Method for creating valve-like mechanism in natural body passageway
US20040215235A1 (en) * 1999-11-16 2004-10-28 Barrx, Inc. Methods and systems for determining physiologic characteristics for treatment of the esophagus
US6551310B1 (en) * 1999-11-16 2003-04-22 Robert A. Ganz System and method of treating abnormal tissue in the human esophagus
US20060095032A1 (en) * 1999-11-16 2006-05-04 Jerome Jackson Methods and systems for determining physiologic characteristics for treatment of the esophagus
US20040087936A1 (en) * 2000-11-16 2004-05-06 Barrx, Inc. System and method for treating abnormal tissue in an organ having a layered tissue structure
US6748255B2 (en) 2001-12-14 2004-06-08 Biosense Webster, Inc. Basket catheter with multiple location sensors
JP2005512667A (en) * 2001-12-20 2005-05-12 レックス メディカル リミテッド パートナーシップ Device for treating gastroesophageal reflux disease
US20040082859A1 (en) * 2002-07-01 2004-04-29 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
WO2004112629A1 (en) 2003-06-20 2004-12-29 Curon Medical, Inc. Devices for treating tissues of the body
US7150745B2 (en) 2004-01-09 2006-12-19 Barrx Medical, Inc. Devices and methods for treatment of luminal tissue
US7959627B2 (en) * 2005-11-23 2011-06-14 Barrx Medical, Inc. Precision ablating device
US8702694B2 (en) * 2005-11-23 2014-04-22 Covidien Lp Auto-aligning ablating device and method of use
US7997278B2 (en) * 2005-11-23 2011-08-16 Barrx Medical, Inc. Precision ablating method
WO2009009443A1 (en) * 2007-07-06 2009-01-15 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation
KR101547931B1 (en) * 2007-07-06 2015-08-28 코비디엔 엘피 Ablation in the gastrointestinal tract to achieve hemostasis and eradicate lesions with a propensity for bleeding
US20090012518A1 (en) * 2007-07-06 2009-01-08 Utley David S Method and Apparatus for Ablation of Benign, Pre-Cancerous and Early Cancerous Lesions That Originate Within the Epithelium and are Limited to the Mucosal Layer of the Gastrointestinal Tract
US8646460B2 (en) * 2007-07-30 2014-02-11 Covidien Lp Cleaning device and methods
US8273012B2 (en) * 2007-07-30 2012-09-25 Tyco Healthcare Group, Lp Cleaning device and methods

Patent Citations (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396019A (en) * 1978-03-06 1983-08-02 Perry Jr John D Vaginal myograph method and apparatus
US4295464A (en) * 1980-03-21 1981-10-20 Shihata Alfred A Ureteric stone extractor with two ballooned catheters
US4706688A (en) * 1981-05-18 1987-11-17 Don Michael T Anthony Non-invasive cardiac device
US5026366A (en) * 1984-03-01 1991-06-25 Cardiovascular Laser Systems, Inc. Angioplasty catheter and method of use thereof
US4765331A (en) * 1987-02-10 1988-08-23 Circon Corporation Electrosurgical device with treatment arc of less than 360 degrees
US5249585A (en) * 1988-07-28 1993-10-05 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
US5056532A (en) * 1989-07-25 1991-10-15 Medtronic, Inc. Esophageal pacing lead
US5103804A (en) * 1990-07-03 1992-04-14 Boston Scientific Corporation Expandable tip hemostatic probes and the like
US5425364A (en) * 1991-02-15 1995-06-20 Cardiac Pathways Corporation Flexible strip assembly without feedthrough holes and device utilizing the same
US5716340A (en) * 1991-08-02 1998-02-10 Scimed Life Systems, Inc. Blood perfusion catheter
US5443470A (en) * 1992-05-01 1995-08-22 Vesta Medical, Inc. Method and apparatus for endometrial ablation
US5341807A (en) * 1992-06-30 1994-08-30 American Cardiac Ablation Co., Inc. Ablation catheter positioning system
US5540655A (en) * 1992-08-12 1996-07-30 Vidamed, Inc. PBH ablation method and apparatus
US5370679A (en) * 1992-10-13 1994-12-06 Atlee, Iii; John L. Esophageal probe for transesophageal cardiac stimulation
US5658278A (en) * 1992-12-01 1997-08-19 Cardiac Pathways, Inc. Catheter for RF ablation with cooled electrode and method
US5657755A (en) * 1993-03-11 1997-08-19 Desai; Jawahar M. Apparatus and method for cardiac ablation
US5395363A (en) * 1993-06-29 1995-03-07 Utah Medical Products Diathermy coagulation and ablation apparatus and method
US5397321A (en) * 1993-07-30 1995-03-14 Ep Technologies, Inc. Variable curve electrophysiology catheter
US5413557A (en) * 1993-08-24 1995-05-09 Pameda N.V. Dilatation catheter with eccentric balloon
US5575787A (en) * 1993-09-20 1996-11-19 Abela Laser Systems, Inc. Cardiac ablation catheters and method
US5651785A (en) * 1993-09-20 1997-07-29 Abela Laser Systems, Inc. Optical fiber catheter and method
US5409458A (en) * 1993-11-10 1995-04-25 Medtronic, Inc. Grooved balloon for dilatation catheter
US5800429A (en) * 1994-06-24 1998-09-01 Somnus Medical Technologies, Inc. Noninvasive apparatus for ablating turbinates
US6056744A (en) * 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US6009877A (en) * 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US5575788A (en) * 1994-06-24 1996-11-19 Stuart D. Edwards Thin layer ablation apparatus
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US6006755A (en) * 1994-06-24 1999-12-28 Edwards; Stuart D. Method to detect and treat aberrant myoelectric activity
US6044846A (en) * 1994-06-24 2000-04-04 Edwards; Stuart D. Method to treat esophageal sphincters
US6092528A (en) * 1994-06-24 2000-07-25 Edwards; Stuart D. Method to treat esophageal sphincters
US6254598B1 (en) * 1994-06-24 2001-07-03 Curon Medical, Inc. Sphincter treatment apparatus
US5454782A (en) * 1994-08-11 1995-10-03 Perkins; Rodney C. Translumenal circumferential energy delivery device
US5785705A (en) * 1994-10-11 1998-07-28 Oratec Interventions, Inc. RF method for controlled depth ablation of soft tissue
US5947964A (en) * 1995-03-03 1999-09-07 Neothermia Corporation Methods and apparatus for therapeutic cauterization of predetermined volumes of biological tissue
US5688267A (en) * 1995-05-01 1997-11-18 Ep Technologies, Inc. Systems and methods for sensing multiple temperature conditions during tissue ablation
US5681280A (en) * 1995-05-02 1997-10-28 Heart Rhythm Technologies, Inc. Catheter control system
US6363937B1 (en) * 1995-06-07 2002-04-02 Arthrocare Corporation System and methods for electrosurgical treatment of the digestive system
US5897553A (en) * 1995-11-02 1999-04-27 Medtronic, Inc. Ball point fluid-assisted electrocautery device
US6066755A (en) * 1995-12-20 2000-05-23 Huels Aktiengesellschaft Amphiphilic compounds with a plurality of hydrophilic and hydrophobic groups based on carbonic acid derivatives
US5718666A (en) * 1996-02-29 1998-02-17 Bioenterics Corporation Transilluminating bougie
US6033397A (en) * 1996-03-05 2000-03-07 Vnus Medical Technologies, Inc. Method and apparatus for treating esophageal varices
US6036687A (en) * 1996-03-05 2000-03-14 Vnus Medical Technologies, Inc. Method and apparatus for treating venous insufficiency
US6015407A (en) * 1996-03-06 2000-01-18 Cardiac Pathways Corporation Combination linear ablation and cooled tip RF catheters
US6066139A (en) * 1996-05-14 2000-05-23 Sherwood Services Ag Apparatus and method for sterilization and embolization
US5776176A (en) * 1996-06-17 1998-07-07 Urologix Inc. Microwave antenna for arterial for arterial microwave applicator
US5800486A (en) * 1996-06-17 1998-09-01 Urologix, Inc. Device for transurethral thermal therapy with cooling balloon
US5891134A (en) * 1996-09-24 1999-04-06 Goble; Colin System and method for applying thermal energy to tissue
US5891027A (en) * 1996-10-21 1999-04-06 Irvine Biomedical, Inc. Cardiovascular catheter system with an inflatable soft tip
US6091995A (en) * 1996-11-08 2000-07-18 Surx, Inc. Devices, methods, and systems for shrinking tissues
US6073052A (en) * 1996-11-15 2000-06-06 Zelickson; Brian D. Device and method for treatment of gastroesophageal reflux disease
US6411852B1 (en) * 1997-04-07 2002-06-25 Broncus Technologies, Inc. Modification of airways by application of energy
US5957920A (en) * 1997-08-28 1999-09-28 Isothermix, Inc. Medical instruments and techniques for treatment of urinary incontinence
US6401719B1 (en) * 1997-09-11 2002-06-11 Vnus Medical Technologies, Inc. Method of ligating hollow anatomical structures
US5967977A (en) * 1997-10-03 1999-10-19 Medtronic, Inc. Transesophageal medical lead
US6589238B2 (en) * 1998-01-14 2003-07-08 Curon Medical, Inc. Sphincter treatment device
US6645201B1 (en) * 1998-02-19 2003-11-11 Curon Medical, Inc. Systems and methods for treating dysfunctions in the intestines and rectum
US6827713B2 (en) * 1998-02-19 2004-12-07 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices
US20040089313A1 (en) * 1998-02-19 2004-05-13 Curon Medical, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
US6464697B1 (en) * 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6689129B2 (en) * 1998-02-27 2004-02-10 James A Baker RF electrode array for low-rate collagen shrinkage in capsular shift procedures and methods of use
US7008419B2 (en) * 1998-05-20 2006-03-07 Shadduck John H Surgical instruments and techniques for treating gastro-esophageal reflux disease
US6802841B2 (en) * 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6740082B2 (en) * 1998-12-29 2004-05-25 John H. Shadduck Surgical instruments for treating gastro-esophageal reflux
US6783523B2 (en) * 1999-05-04 2004-08-31 Curon Medical, Inc. Unified systems and methods for controlling use and operation of a family of different treatment devices
US6733495B1 (en) * 1999-09-08 2004-05-11 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices
US6547776B1 (en) * 2000-01-03 2003-04-15 Curon Medical, Inc. Systems and methods for treating tissue in the crura
US6544226B1 (en) * 2000-03-13 2003-04-08 Curon Medical, Inc. Operative devices that can be removably fitted on catheter bodies to treat tissue regions in the body
US20020162555A1 (en) * 2001-03-26 2002-11-07 Curon Medical, Inc. Systems and methods employing a bite block insert for positioning and stabilizing external instruments deployed within the body
US20020151871A1 (en) * 2001-03-26 2002-10-17 Curon Medical, Inc. Systems and methods employing a guidewire for positioning and stabilizing external instruments deployed within the body
US6699243B2 (en) * 2001-09-19 2004-03-02 Curon Medical, Inc. Devices, systems and methods for treating tissue regions of the body

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070142831A1 (en) * 1998-05-20 2007-06-21 Shadduck John H Surgical Instruments And Techniques For Treating Gastro-Esophageal Reflux Disease
US7507239B2 (en) * 1998-05-20 2009-03-24 Shadduck John H Surgical instruments and techniques for treating gastro-esophageal reflux disease
US20110034975A1 (en) * 2006-05-26 2011-02-10 Ferree Bret A Methods and apparatus for repairing and/or replacing intervertebral disc components and promoting healing

Also Published As

Publication number Publication date
US20020156470A1 (en) 2002-10-24
US6740082B2 (en) 2004-05-25
US7008419B2 (en) 2006-03-07
US8556952B2 (en) 2013-10-15
US20090187181A1 (en) 2009-07-23
US20100191237A1 (en) 2010-07-29
US20130096645A1 (en) 2013-04-18
US20070142831A1 (en) 2007-06-21
US20100042091A1 (en) 2010-02-18
US20040254622A1 (en) 2004-12-16
US7507239B2 (en) 2009-03-24
US20120083780A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
US8556952B2 (en) Surgical instruments and techniques for treating gastro-esophageal reflux disease
AU754424B2 (en) Apparatus to electrosurgically treat esophageal sphincters
US6044846A (en) Method to treat esophageal sphincters
US7167758B2 (en) Medical instruments and techniques for treatment of gastro-esophageal reflux disease
US6092528A (en) Method to treat esophageal sphincters
AU753618B2 (en) Apparatus to electrosurgically treat esophageal sphincters
US6009877A (en) Method for treating a sphincter
JP3879055B2 (en) Electrosurgical sphincter treatment instrument
US20100114087A1 (en) Methods and devices for treating urinary incontinence
US20060015162A1 (en) Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
JP2002508989A (en) Electrosurgical instruments and methods for treating gastroesophageal reflux disease (GERD)
JP2002503513A (en) Instruments for detection of abnormal myoelectric activity and electrosurgical procedures

Legal Events

Date Code Title Description
AS Assignment

Owner name: RESPIRATORY DIAGNOSTIC, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CURON MEDICAL, INC.;REEL/FRAME:020783/0059

Effective date: 20070413

AS Assignment

Owner name: MEDERI THERAPEUTICS, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RESPIRATORY DIAGNOSTIC, INC.;REEL/FRAME:022047/0503

Effective date: 20080912

Owner name: MEDERI THERAPEUTICS, INC.,CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RESPIRATORY DIAGNOSTIC, INC.;REEL/FRAME:022047/0503

Effective date: 20080912

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION